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ABSTRACT 
 
 
MECHANISTIC INSIGHT OF THE ROLE OF NHERF1 IN CISPLATIN-INDUCED 
ACUTE KIDNEY INJURY 
Adrienne M. Bushau-Sprinkle 
January 22, 2020 
 
Background. Acute kidney injury (AKI) develops in 30% of patients who receive 
cisplatin, a widely used chemotherapeutic agent. We previously showed that 
NHERF1 loss resulted in increased susceptibility to cisplatin nephrotoxicity. The 
overarching goal of this dissertation was to elucidate mechanisms of 
susceptibility to cisplatin-induced AKI, specifically the effects of NHERF1 loss on 
tubule cell metabolism, tubule cell mitochondrial function, and alterations in 
oxidative state and/or renal handling of cisplatin. Methods. 2-4 month male wild 
type (WT) and NHERF1 knock out (KO) mice were treated with either vehicle 
control or cisplatin (20 mg/kg dose IP) for 4, 24, and 72 hours. Urine was 
collected for NGAL and kidneys were harvested for histology and the following 
assays: Thiobarbituric Acid Reactive Substances (TBARS) for lipid peroxidation, 
γ-glutamyl transferase (GGT) activity, and Western Blot for GGT and cysteine S-
conjugate beta lyase (CCBL). Mitochondrial respiration was conducted via the 
Seahorse XF24 analyzer on non-treated isolated kidney mitochondria. LC-MS 
vii 
 
analysis was used to evaluate ATP content in non-treated kidneys. Electron 
microscopy was utilized to evaluate mitochondrial morphology and number in 
non-treated kidneys. HPLC of the reduced and oxidized forms of the small 
molecular weight thiols (glutathione (GSH), glutathione disulfide (GSSG), 
cysteine (Cys), and cystine (CySS), and cysteine-glutathione disulfide (CySSG) 
on plasma and kidney cortex. Statistical analysis was completed using Student’s 
t-test for LC-MS, mitochondrial number, and mitochondrial respiration and Two-
way ANOVA was used for all other analysis. P-values of <0.05 were considered 
statistically significant. Results. Chapter III demonstrates that WT and NHERF1 
KO mice do not exhibit metabolic changes or changes in ATP content that would 
definitively sensitize the KO mice to cisplatin injury. Chapter IV shows that 
NHERF1 loss does not affect mitochondrial morphology or mitochondrial number, 
or oxidative phosphorylation capacity via Seahorse XF24 analysis. Thus, 
mitochondrial dysfunction does not appear to sensitize the KO mice to cisplatin 
injury. Lastly, Chapter V reveals that NHERF1 KO mouse kidneys do not exhibit 
changes in lipid peroxidation, oxidative stress, GGT or CCBL protein levels that 
would sensitize these animals to cisplatin. However, NHERF1 KO kidneys 
appear to respond differently to the cisplatin insult itself, characterized by 
differences in GGT activity in response to cisplatin. Conclusions.  In conclusion, 
the work presented in this dissertation reveals that metabolic stress and 
mitochondrial dysfunction are not the mechanisms of susceptibility to cisplatin in 
NHERF1 KO mice. Furthermore, NHERF1 loss does not lead to changes in 
kidney GSH metabolism. In conclusion, these data do not support NHERF1 loss 
viii 
 
resulting in a fundamental metabolic defect that increases susceptibility to 
cisplatin injury. Instead NHERF1 loss appears to influence either the handling, 
the initial insult, or the response to injury resulting in exacerbated injury.  
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CHAPTER I 
 
INTRODUCTION 
 
A. Background and rationale for this study 
 
1. Structure and function of the kidney 
In humans and in most mammals the normal kidney is bean shaped and 
found in pairs within the abdominal cavity behind the peritoneum (1, 2). Each 
kidney is covered by a fibrous capsule with a slit located in the central concave 
portion of the kidney called the hilum (1, 2) (Figure 1.1). The hilum serves as 
both the entry site for the renal artery and the exit site of the renal vein (1, 2). The 
hilum opens into the renal sinus, composed of shallow urine-filled spaces (1, 2). 
Once bisected the kidney is composed of 3 main regions, the cortex, the outer 
medulla, and the inner medulla (1, 2) (Figure 1.1). The cortex is comprised of 
glomeruli (clumps of capillaries) and tubules (convoluted epithelial structures), 
while the medulla lacks glomeruli and consists of parallel arrangements of 
tubules (1, 2).  
The nephron is the functional unit of the kidney and it consists of a 
glomerulus and a tubule (Figure 1.2). The glomerulus is a group of blood vessels 
that forms filtrate from blood plasma, while the epithelial tubule is designed to  
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Figure 1.1 
 
Figure 1.1: Structure of the mammalian kidney. 
The kidney structure includes three regions: an outer cortex, outer medulla, and 
inner medulla. The arteries and veins that support the kidney enter and exit at the 
hilum. Additionally, the hilum serves as a point of exit for the ureter.  
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Figure 1.2 
 
 
Figure 1.2: Structure of the nephron. 
The nephron is the functional unit of the kidney and is responsible for removing 
wastes. Both the glomerulus and the sections of the tubules of the nephron are in 
the cortex of the kidney.  
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convert the blood plasma filtrate into urine (1, 2). Bowman’s capsule surrounds 
the glomerulus and the site where the filtrate passes from the vascular to the 
tubule system (1, 2). The epithelial tubule is divided into multiple subdivisions 
called the proximal tubule, the thin descending and ascending limb of the loop of 
Henle, the thick ascending limb of the loop of Henle, the distal convoluted tubule, 
and the collecting tubule (2) (Figure 1.2). The tubules of the kidney are 
instrumental in recovery of most of the fluid and solutes filtered from the 
glomerulus (1). 
The proximal tubule recovers the vast majority of filtrate from the 
glomerulus and is involved in regulating acid-base balance (2), salt and water 
homeostasis, recovery of filtered glucose and amino acids, as well as divalent ion 
metabolism (1, 2). Additionally, the proximal tubule is the site for organic anion 
and cation transport, including drugs. The loop of Henle creates the conditions 
required for the generation of a concentrated or dilute urine, by pumping salts 
and urea into the medulla to establish the progressively hypertonic cortical to 
medullary gradient within the renal interstitium (1, 2). The creation of this osmotic 
gradient enables the regulated movement of water from tubule to interstitium, 
thus determining urine osmolality. The distal tubule and collecting duct system 
are sites for more precise control of water and salt excretion via several 
hormones (e.g., aldosterone, arginine vasopressin) (1, 2). All of these structures 
collectively enable the kidney to form a filtrate of blood plasma and to selectively 
reabsorb the tubule fluid or secrete solutes into it. 
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2. Importance of the kidney in human health and disease 
The kidneys are multifunctional organs involved in maintaining blood volume, 
total body salt and water balance, acid-base balance, and bone strength and 
integrity (1). The kidneys accomplish these tasks through cooperation with other 
organ systems. Each of these tasks are important in human health, and 
disruption of one or more of these functions can result in complications and/or 
the development of disease (1, 3). 
The human body intakes water, salt, and electrolytes at varying degrees that 
can interrupt the body’s balance of these substances. The kidneys have the 
ability to vary their excretion of electrolytes and water to maintain this balance (1, 
3). Another aspect of this balance of water, salts, and electrolytes is the 
regulation of plasma osmolality, the combined concentration of these substances 
(1, 3). Osmolality is altered whenever the input and output of water and solutes 
shift disproportionally (2, 3). Thus, the kidneys must excrete water and solutes to 
match the intakes at rates that maintain the ratio of solutes and water close to a 
constant value of 292 milliosmoles per kilogram (mOsm/kg) (2, 3). In addition to 
excreting excess amounts of substances the kidney also responds to shortages. 
To accomplish this response the kidneys will reduce the output leading to the 
restoration of this balance of water and solutes (1, 3). One of the major actions of 
the kidney is to regulate all of the electrolytes, body water, and plasma osmolality 
independently (2, 3).  
The kidneys work in tandem with other organ systems including the 
cardiovascular system (1, 2). The kidneys regulate systemic blood pressure by: 
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[1] determining blood volume which controls cardiac output (heart rate x stroke 
volume); and [2] producing hormones that regulate vascular resistance (systemic 
blood pressure/cardiac output) (2, 3). It is vital that the kidneys maintain 
extracellular fluid volume, which includes blood plasma (1-3). This maintenance 
ensures that there is sufficient volume to fill the vascular space, allowing blood to 
circulate normally (1-3). Maintenance of the extracellular fluid volume is a result 
of the kidneys’ regulation of water and salt balance (2, 3). In addition to 
maintaining adequate volume of the cardiovascular system, the kidneys produce 
vasoactive substances (e.g., renin-angiotensin-aldosterone system) that help 
control vascular smooth muscle (2, 3). This influences peripheral vascular 
resistance and consequently systemic arterial blood pressure (1-3). Disruption of 
this aspect of renal function leads to the development of hypertension (1, 3).  
The human body constantly forms the end products of metabolic processes, 
which must be excreted at the same rate that they are produced (1, 2). These 
products include urea from protein, uric acid from nucleic acids, creatinine from 
muscle creatinine, urobilin from hemoglobin breakdown, and the metabolites of 
various hormones and biochemical processes (2, 3). Collectively these products 
are called uremic toxins when they accumulate under conditions of kidney failure 
(3), and contribute to uremia, the constellation of clinical features characteristic of 
advanced chronic kidney disease (CKD) (1, 3). In addition, the kidneys are 
responsible for the excretion of many types of drugs. Frequently these drugs 
damage the kidneys leading to alterations in kidney function. 
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Although the kidneys are responsible for excretion of hormones and their 
metabolites, they are also involved in production of the hormone erythropoietin 
(1-3). Interstitial cells located in the cortical intersititum (border between renal 
cortex and medulla) secrete this hormone that stimulates the production of red 
blood cells in the bone marrow (1, 2). The reduction of partial oxygen pressure 
stimulates the kidney cells to secrete erythropoietin (2, 3). In cases of anemia, 
blood loss, or insufficient blood flow to the kidneys the local oxygenation drops 
and triggers secretion of erythropoietin (1-3).  
The kidneys in combination with the gastrointestinal (GI) tract are essential 
regulators for phosphate and calcium homeostasis, which is necessary for bone 
health (1-3). The kidneys accomplish this homeostasis through the production of 
calcitriol (active form of vitamin D) (1-3). Calcitriol helps increase calcium 
absorption from the intestine into the blood. CKD can disrupt this process and 
cause a form of bone disease, renal osteodystrophy (1, 3). Moreover, the 
impaired bone metabolism is accompanied by calcium-phosphate deposits in 
blood vessels, increasing the risk of heart disease (3).  
Lastly, the kidneys are responsible for maintaining tight control of acid-base 
balance and they are a site of gluconeogenesis (body’s process of producing 
glucose from non-carbon sources) (1-3). Disruption in acid-base balance can 
lead to life-threatening conditions such as metabolic acidosis and alkalosis (1-3). 
Loss of gluconeogenesis can result in hypoglycemia in advanced CKD, 
particularly under conditions of stress or nutrient deficiency. 
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Altogether the kidney is a unique organ that is involved in many vital 
processes. The kidneys excrete many substances and help maintain the body’s 
homeostasis. Equally important to the kidneys’ ability to excrete waste, the 
kidneys also work in partnership with other organ systems through production of 
hormones. Consequently, alterations in any of these processes can lead to 
complications and the development of disease in the body, further illustrating the 
importance of the normal functioning kidney to overall human health. 
 
3. Acute kidney injury 
Acute kidney injury (AKI) is defined as an abrupt decline in kidney function, 
and is a common clinical condition; approximately 20% of all hospital admissions 
are related to AKI (4). 2-300 per million cases of AKI are severe enough to 
require dialysis (5). Meanwhile, 2-3000 per million cases of AKI do not require 
dialysis (5). In the critical care setting close to two thirds of patients will develop 
AKI and around five percent of intensive care unit (ICU) patients will develop 
severe cases of AKI that warrant dialysis (5). AKI is associated with a four-fold 
increase in mortality and is a risk factor for the development of CKD (5).  
AKI can be divided into three pathophysiological categories: pre-renal, 
intrinsic, and post-renal (obstructive) (2). Pre-renal AKI results from a decrease in 
arterial blood volume leading to kidney hyperfusion (2), but without intrinsic 
damage to the kidney tissue. Hemorrhage from trauma or surgery, septic shock, 
and cirrhosis are all conditions that can lead to the development of pre-renal AKI 
(2). Intrinsic AKI occurs from direct damage to the kidneys resulting in a sudden 
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loss in kidney function. The common causes are acute tubular necrosis (ATN), 
acute glomerulonephritis (AGN), and acute interstitial nephritis (AIN) (2). 
Ischemic and septic ATN are the most common causes of intrinsic AKI, however, 
ATN can result from drug toxicities (2). AGN can be the result of autoimmune 
diseases, such as Lupus Nephritis, which can damage and inflame the glomeruli 
of the kidneys (2). AIN manifests as severe inflammation of the kidneys. This 
inflammation is usually the result of medications, such as antibiotics or a 
nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen or ibuprofen 
(2). Additionally, AIN can be caused by streptococcal, viral, or Legionella 
infection (2). Post-renal AKI is commonly induced by the obstruction of the 
ureters, bladder outlet, or urethra (2). These obstructions may be due to prostatic 
conditions, anticholinergic agent therapy, blood clots, or ureter fibrosis (2). From 
herein the focus of this dissertation will focus on drug-induced intrinsic AKI.  
Drugs are the third to fifth leading cause of AKI in critically ill patients (6) 
consistent with the kidneys’ role in concentrating and excreting toxic metabolites 
and drugs (7), making them a common site of drug toxicity. Drugs damage the 
kidneys by several mechanisms: [1] vasoconstriction, [2] altered intraglomerular 
hemodynamics, [3] tubular cell toxicity, [4] interstitial nephritis, [5] crystal 
deposition, [6] drug-induced thrombotic microangiopathy, [7] osmotic nephrosis, 
and [9] rhabdomyolysis.  
Vasoconstriction is the mechanism of nephrotoxicity of calcineurin inhibitors, 
vasopressors, and contrast agents (7). The use of NSAIDs, angiotensin 
converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARB) 
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can lead to altered intraglomerular hemodynamics resulting in a decline in kidney 
function (7). The proximal tubule is particularly vulnerable to toxic injury due to its 
role of reabsorbing the glomerular filtrate. Tubular cell toxicity is seen in a dose-
dependent manner for many drugs (e.g. aminoglycosides, amphotericin, 
calcineurin inhibitors, cisplatin, methotrexate, and antivirals) causing kidney injury 
(7), while crystal deposition in the distal tubular lumen is pH-dependent and 
commonly seen in nephrotoxicity associated with acyclovir, sulfonamide, 
methotrexate, indinavir, and triamterene (7). Additionally, uric acid and calcium 
phosphate crystals are observed following chemotherapy (7). Drug-induced 
thrombotic microangiopathy has been reported with mitomycin, cyclosporin, 
tacrolimus, interferon, and quinine (7). Osmotic nephrosis has been associated 
with high doses of mannitol and immunoglobulins (7) and results from 
hyperoncotic solutions by decreasing glomerular filtration rate (GFR) or from 
osmotically induced tubular damage (7).  
Unfortunately, the need for many of these medications outweighs the risk of 
nephrotoxicity development. During these instances measures are taken to 
minimize the drug-induced kidney damage, but these measures are not always 
successful. For these reasons innovative and novel research is needed toward 
the prevention of drug-induced AKI.  
 
4. History of cisplatin in the clinic 
Cisplatin is a widely used chemotherapeutic to treat a variety of solid 
malignant tumors (e.g. head and neck, ovarian, testicular, and lung cancer) (8).  
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As discussed previously, cisplatin is associated with proximal tubule toxicity in 
AKI. To fully understand cisplatin’s efficacy in the clinic despite its toxicity, it is 
important to also understand its development and long history of use clinically. 
The biological effects of platinum were discovered in 1961 by a physicist, 
Barnett Rosenberg, while examining if alternating electromagnetic forces could 
affect cell division (9). Rosenberg set up platinum conducting plates in a chamber 
with Escherichia coli (E. coli) grown on a medium containing ammonium chloride, 
which provided the nitrogen required for cell growth (9). Rosenberg then applied 
an electric current and observed that the E. coli stopped dividing (9). He carried 
out further experiments to determine what was inhibiting the cell division, and 
discovered it was the platinum when combined with ammonia molecules (9). This 
discovery led to the further development of using platinum complexes as anti-
tumor agents. A number of platinum complexes were tested, however, only the “-
cis” complexes with adjacent ammonia groups displayed anti-tumor activity (9). In 
1969 the cisplatin (cis-diammine-dichloroplatinum (II)) compound was discovered 
to have the most potent anti-tumor effects (9). Cisplatin has a central platinum 
atom bound by ammonia and chloride groups in a square planar structure (10) 
(Figure 1.3). Cisplatin forms DNA crosslinks which interrupt cellular DNA 
functioning and induces apoptosis (10). This is accomplished through the two 
“leaving” chloride groups which readily dissociate in physiological conditions, and 
the subsequent formation of a platinum-DNA adducts that can only be repaired 
using nucleotide excision repair (10). 
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Figure 1.3 
 
Figure 1.3: Structure of cis-diamminedichloroplatinum (II) or cisplatin. 
Molecular structure of cisplatin is a square planar complex with two labile 
chlorine and two inert ammonia molecules that are coordinated to the central 
platinum (II) atom in the cis configuration. 
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Following pre-clinical and human studies cisplatin was approved by the Food 
and Drug Administration (FDA) in 1978 for the treatment of advanced metastatic 
testicular, ovarian and bladder cancer (11). Since then it has had great success 
as a chemotherapeutic agent and is one of the most widely used anti-tumor 
drugs in the world. For example, in the early 1970s metastatic testicular cancer 
was associated with a 5% survival rate (12). Improved surgical techniques in 
combination with cisplatin chemotherapy has increased the 5-year survival rate 
for men with testicular cancer to 95% (12). Furthermore, as recently as 2010 
there were over 500 active clinical trials involving cisplatin (13), underlying its 
continued prominent use in the treatment of solid malignant tumors. 
Unfortunately, the major limiting factor of cisplatin is its nephrotoxicity.  
The first report of cisplatin’s nephrotoxicity was in 1971 during pre-clinical 
animal studies (13). These studies found histopathologic changes of ATN along 
with azotemia (abnormally high levels of nitrogen containing compounds in the 
blood). Early clinical use of cisplatin saw dose-related renal failure in 14-100% of  
patients, with the incidence varying with the cumulative dose (13). This high 
severity of toxicity almost prevented cisplatin’s FDA approval as a 
chemotherapeutic agent (8, 14). In response, hydration protocols were 
developed that reduced the nephrotoxicity and allowed the implementation of 
increased doses to reach therapeutic levels (8, 15). Subsequently, cisplatin alone 
and in combination based chemotherapy regimens are currently used as a front-
line therapy for testicular cancer, ovarian germ cell tumors, epithelial ovarian 
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cancer, head and neck cancer, advanced cervical cancer, bladder cancer, 
mesothelioma, endometrial cancer, non-small cell lung cancer, malignant 
melanoma, carcinoids, penile cancer, and adrenocortical carcinoma (8). 
Additionally, it is used as a consolidation therapy for many types of solid tumors 
that have failed standard treatment regimens (8). Even though cisplatin is widely 
used, and hydration protocols decreased the incidences of kidney injury, cisplatin 
is still associated with a risk of 20-30% of patients developing AKI after a single 
dose. Research has been ongoing to both understand how cisplatin damages the 
kidney and to discover preventative methods. 
 
5. Cisplatin and the kidney 
Nephrotoxicity is an unusual side effect of a chemotherapeutic agent in 
general. In most cases chemotherapy drugs target pathways that are essential 
for cell division and therefore rapidly dividing cells such as bone marrow cells are 
most sensitive to these agents. Thus, the high rate of nephrotoxicity in the kidney 
which as a low cell turnover rate is unexpected and indicates that cisplatin may 
have two distinct mechanisms that kill cells, one for highly prolific cancer cells 
and one for quiescent kidney cells. 
 Cisplatin is cleared by the kidney via glomerular filtration and tubular 
secretion (13, 16). Concentration of cisplatin is higher in the kidney than in the 
blood suggesting there is active accumulation of the drug by renal parenchymal 
cells (8, 13). Even though cisplatin was developed over 50 years ago, its 
mechanism of toxicity is not completely understood. Previous studies provided 
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evidence that cisplatin undergoes a basolateral-to-apical transport within the 
kidney (13, 17). In more recent years studies have identified two membrane 
transporters that are capable of cisplatin uptake: copper transporter 1 (Ctr1) and 
organic cation transporter 2 (OCT2) (13). Both Ctr1 and OCT2 are highly 
expressed in the kidney and found in the basolateral membrane of the proximal 
tubule (Figure 1.4). Downregulation of Ctr1 protein expression in kidney cells 
decreases cisplatin uptake within the kidney (13, 18). Likewise, OCT2 knock out 
(KO) mice demonstrate significantly reduced cisplatin urinary excretion and 
nephrotoxicity (13, 19, 20). Furthermore cimetidine, an OCT2 substrate, also 
reduced cisplatin uptake and cytotoxicity in vitro (18, 21), and patients with a 
nonsynonymous single-nucleotide polymorphism (SNP) in the OCT2 gene 
(rs316019) demonstrated a reduced cisplatin-induced nephrotoxicity (13, 19, 20). 
Another membrane protein, the multidrug and toxin extrusion 1 (MATE1) protein, 
is responsible for cisplatin extrusion out of the proximal tubule into the tubular 
lumen (Figure 1.4). MATE1 KO mice also exhibited enhanced cisplatin 
nephrotoxicity (22). Taken together these studies suggest that the cell 
mechanisms for cisplatin transport in the proximal tubule play a critical role in 
determining the susceptibility to injury. In addition to renal cisplatin uptake, there 
is evidence that cisplatin undergoes a biotransformation to a more potent toxin in 
the kidney (Figure 1.4). Studies in rats and mice show that the process may 
begin with the formation of glutathione-conjugates in the circulation, possibly 
mediated by glutathione-S-transferase (13, 23, 24). In the kidney these 
glutathione-conjugates are extruded by MATE1 and further cleaved to cysteinyl- 
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Figure 1.4 
 
Figure 1.4: Cisplatin metabolism to a nephrotoxin. 
Cisplatin enters the renal proximal tubule cell and is conjugated to glutathione 
(GSH). MATE-1 is responsible for exodus of cisplatin and cisplatin-glutathione 
conjugates into the tubule lumen. γ-glutamyl transpeptidase (GGT) and 
aminodipeptidase (AP) further metabolize cisplatin-glutathione conjugates to 
cisplatin-cysteinyl and cysteine conjugates. The cisplatin-cysteine conjugate re-
enters the renal proximal tubule cell and cysteine-S-conjugate beta-lyase 
metabolizes it to an unstable and reactive cisplatin-thiol conjugate, the 
nephrotoxic metabolite of cisplatin. 
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glycine-conjugates by γ-glutamyl transpeptidase (GGT) (Figure 1.4), expressed 
apically in the proximal tubule (13, 25, 26). The cysteinyl-glycine-conjugates are 
further metabolized to cysteine-conjugates by aminopeptidases (AP) (Figure 1.4), 
also expressed apically (13, 25, 26). The cysteine-conjugates are transported 
back into the proximal tubule by an unknown protein transporter where they are 
further metabolized by cysteine-S-conjugate beta lyase (CCBL), forming a highly 
reactive thiol (13, 25-27) (Figure 1.4). This reactive thiol is what is believed to 
cause the toxicity. Experiments show that blocking any of these enzymes 
ameliorates cisplatin nephrotoxicity.  
Renal tissue damage, characterized by tubular cell death, is a frequent and 
common occurrence of cisplatin nephrotoxicity. Subsequently renal tubule cell 
death may be in the form of apoptosis and necrosis. Necrotic cell death has been 
observed with high concentrations of cisplatin, whereas lower concentrations led 
to apoptosis in vitro (12, 28). In animal models both apoptosis and necrosis can 
be observed following cisplatin administration (12, 29). Although there has been 
a great deal of investigation into the mechanism of cisplatin-induced 
nephrotoxicity there are still many unanswered questions. As a result, it is still not 
understood why some patients are more susceptible to cisplatin nephrotoxicity. 
To develop either renoprotective strategies or therapies more research is needed 
regarding mechanisms of susceptibility along with identifying novel targets that 
do not affect cisplatin’s efficacy. One such target recently discussed is the Na/H 
exchange regulatory factor 1 (NHERF1) scaffolding protein.  
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6. NHERF1: is it more than an anchor? 
Cells communicate through coordinated signaling networks that rely on 
scaffolding proteins, which organize multiprotein complexes and enable proper 
transmission of information. NHERF1 is a member of a post-synaptic density 
protein 95/Drosophila Discs Large/Zonula Occulens -1 (PSD-95/DIg/ZO-1) 
homology (PDZ) scaffolding protein family. NHERF1 has two tandem PDZ 
domains, a carboxy terminal ezrin binding domain, and a CRAC (cholesterol 
binding) domain. Initially NHERF1 was identified (30) as an organizer and 
regulator of hormone receptors, signal transduction pathways, and transporters 
through its interaction with actin-binding-ezrin-radixin-moesin (ERM) proteins on 
the apical side of epithelial cells (31, 32). NHERF1 has many known functions in 
the kidney including: regulating the sodium hydrogen antiporter 3 (NHE3) 
function via the parathyroid hormone (PTH), regulating and anchoring the sodium 
phosphate co-transporter type-2 (Npt2a) expression by PTH and dopamine, and 
regulating the sodium pump. More recently NHERF1 has been found to be 
involved in a variety of functions across multiple cell types including: cell 
structure and trafficking, tumorigenesis and tumor behavior (33, 34), 
inflammatory responses (2, 18), and tissue injury (35-37). There have been a 
number of divergent and contradictory reported effects of NHERF1, making it 
difficult to predict how either the absence or the overexpression of NHERF1 will 
affect a specific cell function. 
Cell Structure 
19 
 
NHERF1 plays a role in actin cytoskeleton organization (38), cell polarity (39), 
and trafficking (40) possibly though its ability to scaffold signaling complexes via 
its interaction with ERM proteins. NHERF1 disrupts the actin skeleton in HeLa 
cells, thought to be through increased α actinin IV ubiquitination and degradation 
(38); however, in Madin-Darby-canine-kidney (MDCK) cells NHERF1 enhances 
actin skeleton organization (41) stimulated by podocalyxin-induced RhoA 
activation through the Rho/Rho-associated coiled-coil protein kinase (ROCK) 
pathway (42).   
There are multiple functional consequences of the actin cytoskeleton 
organizational role of NHERF1. NHERF1 colocalization with proteins has been 
implicated in cell polarity through tight junction formations (39) and protein 
targeting to the apical or basolateral membrane (43-45). NHERF1 has a 
significant role in protein anchoring and assembly of multi-protein complexes. For 
example, NHERF1 expression is critical for assembling G-protein-coupled 
receptors (GPCRs), downstream signaling molecules (e.g. adenylyl cyclase), and 
target proteins such as Npt2a and the NHE3 in the proximal tubule. Additionally, 
NHERF1 is essential for regulating total body phosphate homeostasis by 
anchoring Npt2a through ezrin binding and subsequently the NHERF1 KO 
mouse displays phosphaturia and uricosuria (46). 
In addition to membrane targeting NHERF1 may also play a role in 
establishing cell phenotype. NHERF1 mediated plasma membrane expression of 
the calcium adenosine triphosphatase (Ca-ATPase) 2 prevented involution of 
20 
 
lactating mammary gland cells through suppression of the signal transducer and 
activator of transcription 3 (Stat3) activation (43). 
Cancer 
NHERF1 exhibits a dual role in tumorigenesis that is dependent on its 
expression or subcellular localization. When NHERF1 is located at the plasma 
membrane it acts as a tumor suppressor (47). In contrast, NHERF1 expression 
loss, cytoplasmic or nucleus localization results in pro-oncogenic properties (47). 
This phenomenon has been observed in melanoma (48), breast (49-54), 
reproductive system (55-58), digestive system (59-63), liver (64-66), lung (67), 
and brain cancers (68-71). Potential mechanisms for the effect of NHERF1 on 
tumor behavior include: inhibition of the epidermal growth factor receptor (EGFR) 
signaling due to a decreased interaction with NHERF1 (72), increased 
cytoplasmic expression of vascular endothelial growth factor (VEGF) and its 
receptor VEGFR1 (73), alteration in mineral metalloproteinase expression (74), 
and enhanced Wnt1 signaling (75). Furthermore, NHERF1 overexpression has 
been linked in liver cancer cells, regulation of cell cycle (45, 76, 77), and 
suppression of reactive oxygen species (ROS) (78). 
Cytoplasmic localization of NHERF1 has been implicated in the development 
of metastatic cancers (79). A potential mechanism may involve differential 
phosphorylation of NHERF1, where NHERF1 creates protein complexes which 
either activate or inactivate the promotion of metastatic behavior (80). For 
instance, overexpression of NHERF1 has been associated with pro-metastatic 
behavior in breast cancer cell lines. Moreover, overexpression of NHERF1 was 
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connected with enhanced cell functions associated with the metastatic phenotype 
and mitigated by mutations of the phosphorylation sites S279 or S301 in 
NHERF1. NHERF1 phosphorylation is also essential for tumor-induced 
angiogenesis (80).  
Inflammation and fibrosis 
ROS impacts aging/fibrosis, cancer, neurodegenerative disorders, and 
cardiovascular disease (81). Interestingly, NHERF1 has been found to be a 
binding partner and regulator of NADPH oxidase (Nox1) by directly associating 
with the Nox organizing subunit p47phox.  Additionally, NHERF1 interacts with 
other proteins involved in inflammatory pathways including the interleukin 8 (IL8) 
receptor beta, C-X-C Motif light-chain-enhancer of activated B cells (NF-B), and 
simultaneously increased NF-B production.   
A study using a rat aging model found NHERF1 expression loss was 
associated with renal fibrosis development (84). One potential mechanism is 
suggested by the observation that NHERF1 blunted the transforming growth 
factor beta 1 (TGF-β1) expression of mesenchymal cell markers in a lung cancer 
cell line (85). Additionally, a role for NHERF1 in regulating epithelial-
mesenchymal transition (EMT) is another possibility in lieu of previously cited 
studies where NHERF1 plays a role in cell polarity, cell phenotype expression, 
and cell cycle regulation.  
Response to injury 
NHERF1 expression has been implicated in responses to injury. In a model of 
cholestatic liver injury induced by bile duct ligation the NHERF1 KO mouse 
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exhibits attenuated liver injury (36). Loss of NHERF1 also resulted in the deletion 
of the ICAM-1-ERM-NHERF1 complex resulting in a reduction in both hepatic 
ICAM1 and ERM proteins, which are essential for neutrophil mediated cholestatic 
liver injury (36). Therefore, NHERF1 may have a sensitizing role in inflammatory 
induced liver injury. On the other hand, NHERF1 loss does not result in 
protection against cisplatin-induced AKI. In fact NHERF1 KO mouse kidneys 
were more susceptible to cisplatin-induced AKI (35), exhibiting a decrease in 
renal function, a significant increase in urine neutrophil gelatinase-associated 
lipocalin (NGAL), and severe histologic damage (casts, BBM sloughing, and 
ATN) when compared to cisplatin treated wild type (WT) mice. 
Interestingly the absence of NHERF1 protected against liver tissue injury in 
the biliary ligation model, but increased sensitivity to injury in the cisplatin-
induced AKI model. Thus, NHERF1 may have a significant role in the severity of 
injury after specific insults and in specific tissues potentially due to regulation of 
the acute inflammatory response.  
Implications for renal physiology/pathophysiology 
NHERF1 has a much broader role than as a scaffold or anchor in the cell, 
illustrated by the effect NHERF1 has on a variety of diseases and tissues along 
with its contributions to cell growth and proliferation, cell polarity and structure, 
determination of cell phenotype, response to inflammation, and neoplastic 
transformation. For this dissertation the role NHERF1 plays in susceptibility to 
cisplatin-induced AKI (35) will be further investigated. However, many questions 
remain including: whether NHERF1 is a primary mediator or responder of kidney 
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injury and if NHERF1 can be used as a biomarker or therapeutic target for the 
prevention of kidney injury. 
 
 7. Metabolism and susceptibility to cisplatin toxicity 
As previously discussed, the accumulation and bioactivation of cisplatin to a 
more potent nephrotoxic metabolite underlies the kidney’s susceptibility to 
cisplatin-induced AKI. Recent studies have found that cisplatin alters renal cell 
metabolism, contributing to injury and the common occurrence of CKD 
development. 
Several studies have found that cisplatin treatment leads to renal tubular cell 
depletion of amino acids, caused by both elevated levels of aminoaciduria and 
decreased tubular reabsorption of amino acids (86-89). Interestingly, branched-
chain amino acids such as leucine, isoleucine, and valine were found to be 
elevated in urine and decreased in serum (86, 90). Many have discussed if this 
phenomenon could be used as either a biomarker for prediction of susceptibility 
to nephrotoxicity or enable earlier detection of kidney injury following cisplatin 
treatment (86). Moreover, cisplatin influences lipid metabolism through the 
reduction of fatty acid oxidation resulting in accumulation of fatty acids in kidney 
tissue (86, 89, 91). Likewise, diacylglycerols, triacylglycerols, ceramides, and 
neutral lipids accumulate in kidney tissue (86, 87, 92). Cisplatin also impacts 
glycolysis through the reduction of glycolytic enzymes, thus, glucose will 
accumulate while metabolites of glycolysis decrease (86, 93). In addition to 
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glycolysis, cisplatin also decreases intermediates of the pentose phosphate 
pathway and the citric acid cycle (86, 94).  
These observations bring into question if susceptible patients could have an 
altered renal cell metabolism, consequently, predisposing these patients to 
nephrotoxic injury from cisplatin. This hypothesis will be further discussed and 
investigated later in this dissertation.  
 
 8. Mitochondrial dysfunction and susceptibility to cisplatin toxicity 
It has been well established that cisplatin nephrotoxicity induces cell death via 
both apoptosis and necrosis. However, the mechanisms by which cisplatin 
induces these pathways remains unclear. Recent evidence reveals that ROS and 
mitochondrial function play an important role in cisplatin’s mechanism of injury 
(95). Mitochondria continuously produce ROS, such as superoxide, and 
scavenge these ROS using antioxidant enzymes (superoxide dismutase, 
glutathione peroxidase, catalase, and glutathione S-transferase) (96). Moreover, 
cisplatin has been found to also accumulate in the mitochondria of renal epithelial 
cells (97, 98). Several studies show that cisplatin induces ROS in renal epithelial 
cells by decreasing the activity of antioxidant enzymes along with the depletion of 
intracellular glutathione (GSH) concentrations (99-102). Furthermore, there are 
additional studies that demonstrate that pre-treatment with antioxidants such as 
GSH is beneficial in reducing cisplatin’s nephrotoxicity (103, 104). 
However, other studies suggest that at least in cultured proximal tubule cells, 
the primary cause of cell death post cisplatin treatment may be far more related 
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to mitochondrial dysfunction than ROS formation (100, 105). Several of these 
studies show that cisplatin induces mitochondrial dysfunction, primarily through 
targeting enzymatic complexes that comprise the electron transport chain (ETC) 
(100, 105). Once the ETC is compromised, proximal tubule cells show a 
significant reduction in ATP, with a rapid metabolic collapse and necrotic cell 
death (28, 106). Additionally, slighter amounts of ATP depletion in tubule cells 
have been associated with lower doses of cisplatin (106, 107). Lower amounts of 
ATP depletion lead to apoptosis through the release of mitochondrial cytochrome 
c in tubule cells (106, 107). Similarly, to other aspects of cisplatin injury, the 
mechanism by which cisplatin causes cytochrome c release remains 
controversial. Two proposed mechanisms include induction of mitochondrial 
permeability transition (107) and increases in mitochondrial transmembrane 
potential (106). Likewise, the mechanism behind cisplatin’s ability to inhibit the 
enzymatic complexes of the ETC are also unclear.  
If ATP depletion and mitochondrial dysfunction play a central role in cisplatin-
induced cell death, then how does one explain the supporting evidence for ROS 
formation triggering cell death following cisplatin exposure? One possibility is that 
these two processes co-exist, and are not mutually exclusive in regards to 
cisplatin-induced cell death (8). It is possible that while the amount of ATP 
depletion may induce the primary cell injury and influence the cell death pathway, 
it may also accelerate ROS formation from the damaged cells (8), thus, 
contributing to an amplification loop leading to ROS mediated cell death (8). 
Especially since reduction in ROS through the pre-treatment of antioxidants can 
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alleviate nephrotoxicity (103, 104), this may limit this amplification loop and 
reduce the accompanying inflammatory response (100).  
Collectively, it is evident that both ROS production and mitochondrial 
dysfunction remain conceivable mechanisms of cisplatin-induced renal cell 
death. With this knowledge it brings into question if renal cells containing higher 
amounts of ROS and/or mitochondrial dysfunction could prime these cells for a 
‘second hit’ with cisplatin, therefore, sensitizing these cells to cisplatin 
nephrotoxicity and possibly clarifying why some patients are more susceptible to 
cisplatin-induced AKI. This proposed mechanism will be further investigated 
throughout this dissertation.   
 
9. Statement of goals 
It is well established that cisplatin’s limiting factor is its nephrotoxicity, but the 
mechanism of toxicity remains uncertain. Moreover, there are no methods to 
predict which patients are susceptible to injury and there are no targeted 
therapies to halt or reverse the development of AKI. Development of such 
methods or therapies requires a better understanding of mechanisms of disease 
progression as well as identification of novel drug targets. Therefore, one goal of 
this dissertation is to shed new insight into mechanisms of susceptibility to 
cisplatin-induced AKI. Additionally, it has been established that loss of the 
NHERF1 protein in mice predisposes these animals to cisplatin nephrotoxicity 
(35). Another goal of this dissertation is to elucidate mechanisms by which 
NHERF1 loss affects the kidneys. Taken together, the goal of this dissertation is 
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to both understand the role NHERF1 plays in cisplatin nephrotoxicity and to 
speculate on its potential use as a biomarker and/or therapeutic target.   
 
B. Aims and proposals 
 
1. Characterization of metabolic differences in kidneys of WT and 
NHERF1 KO mice 
As discussed in earlier sections, cisplatin significantly alters areas of 
metabolic function and cellular homeostasis. In addition, mitochondria are 
essential for maintaining this homeostasis. Mitochondria are responsible for ATP 
production and in regulating the cell death pathways of apoptosis and necrosis. 
Our laboratory has also established that loss of the NHERF1 scaffolding protein 
predisposes mice to cisplatin-induced AKI (35). Understanding the mechanism of 
susceptibility of these animals may be beneficial in understanding disease 
development of cisplatin-induced AKI along with potentially providing future 
therapeutic targets. Preliminary data from our laboratory suggested that NHERF1 
KO mice may have an altered metabolic function. This was in part supported by 
proteomic analysis of the brush border membrane (BBM) of WT and NHERF1 
KO mouse kidneys. This analysis showed notable decreases in mitochondrial 
proteins in the NHERF1 KO BBM. Furthermore, Seahorse XF24 analysis of 
isolated proximal tubule cells from WT and NHERF1 KO mouse kidneys 
exhibited a decrease in oxygen consumption rate (OCR). These results suggest 
that metabolic changes may play an important role in the sensitization of the 
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NHERF1 KO kidney to insult. This is supported by the following: [1] NHERF1 
deficient cells do not grow as rapidly as normal proximal tubule cells, suggesting 
that these cells are stressed. [2] NHERF1 KO mice treated with cisplatin display 
a significant increase in BUN levels that are consistent with a more severe renal 
injury when compared with treated WT mice (35). [3] Semi-quantitative scoring in 
a blinded study showed cisplatin treated NHERF1 KO kidneys have a higher 
level of severity in injury based on number of tubular casts, degree of ATN, and 
BBM sloughing (35). [4] Levels of apoptosis are similar between cisplatin treated 
WT and NHERF1 KO kidneys, indicating that damaged NHERF1 KO kidneys 
may have a higher level of ATP depletion resulting in higher levels of necrotic cell 
death (35). [5] Anaerobic glycolysis, a hallmark of AKI, is known to increase in 
rodent models treated with cisplatin (108) and in models of ischemic reperfusion 
(109) concomitant with a decrease in aerobic metabolism. The goal of this aim 
was to define any metabolic differences between kidneys of WT and NHERF1 
KO mice. This study evaluated gluconeogenic, glycolytic, and pentose phosphate 
enzyme activity along with measuring ATP content of WT and NHERF1 KO 
mouse kidneys under basal and cisplatin treated conditions. 
 
2. Identification of changes in mitochondrial function in NHERF1 KO 
mice kidneys 
Cisplatin is known to accumulate in renal cell mitochondria and can damage 
mitochondrial enzymatic complexes. Additionally, mitochondrial dysfunction is 
one potential mechanism of cisplatin-induced renal cell death. It was 
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hypothesized that an underlying mitochondrial dysfunction in NHERF1 KO 
kidneys may lead to sensitization of cisplatin nephrotoxicity. Furthermore, two 
proposed potential causes of mitochondrial dysfunction were: [1] Decrease in 
mitochondrial OCR also known as oxidative phosphorylation and/or alterations in 
mitochondrial structure in NHERF1 KO kidneys. [2] Decrease in number of 
mitochondria in NHERF1 KO kidneys. Therefore, electron microscopy (EM) was 
utilized to analyze both the mitochondrial morphology, distribution, and number of 
mitochondria in WT and NHERF1 KO kidneys. Additionally, mitochondria were 
isolated from WT and NHERF1 KO kidneys to evaluate function using the 
Seahorse XF24 Analyzer. This builds upon the work in Aim 1 of this dissertation, 
further evaluating metabolic and mitochondrial homeostasis as a potential 
mechanism of susceptibility to cisplatin nephrotoxicity in NHERF1 KO mice.  
 
3. Identification of mechanisms for enhanced cisplatin injury in 
NHERF1 KO mice 
Recently, a study showed that cervical cancer cells that are NHERF1 
deficient have cisplatin resistance (110). Our laboratory previously established 
that NHERF1 KO mice have exacerbated cisplatin nephrotoxicity (35). 
Collectively, these data suggest that loss of NHERF1 may alter cisplatin cellular 
uptake and/or metabolism. Cisplatin metabolism begins with conjugation to GSH 
and within renal proximal tubule cells results in a nephrotoxic metabolite, 
cisplatin-thiol conjugate which is reactive and unstable and thus damages the 
mitochondria (111). Previous studies in mice and rats found that inhibition of 
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GGT and CCBL, involved in cisplatin metabolism, blocked the nephrotoxic effects 
of cisplatin (26, 112, 113). In in vitro studies, different cisplatin GSH conjugates 
led to more cell death to tubule cells than cisplatin alone (114). Aim 3 of this 
dissertation tests the hypothesis of potential changes in renal handling of 
cisplatin in NHERF1 KO mice. This was tested through the evaluation of lipid 
peroxidation, levels of small molecular weight thiols that act as antioxidants (e.g. 
GSH and Cysteine (Cys)), enzymatic activity of GGT, GGT and CCBL protein 
levels via western blot, and localization of GGT. Additionally, multiple time points 
(4 hours, 24 hours, and 72 hours) were evaluated based upon the established 
pharmacokinetics of cisplatin (115, 116).  
 
Overall aim of this dissertation. 
The overall aim of this dissertation is to provide new insight into mechanisms 
of susceptibility to cisplatin-induced AKI. To this end, the role of NHERF1 and 
sensitivity to cisplatin is a novel hypothesis that has not previously been 
investigated. Additionally, 3 potential mechanisms of susceptibility were 
investigated in this dissertation. [1] metabolic changes in NHERF1 KO mice 
kidneys (Aim 1) [2], mitochondrial function, morphology, and number in NHERF1 
KO kidneys (Aim 2) [3], altered renal handling of cisplatin in NHERF1 KO kidneys 
(Aim 3). Taken together, this work will shed new mechanistic insight into 
cisplatin-induced AKI. 
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CHAPTER II 
 
EXPERIMENTAL PROCEDURES 
 
A. Animals and treatments 
Animal experiments were carried out by the Lederer laboratory. Mice were 
housed in a pathogen-free barrier facility, accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care. All animals used in 
these studies and procedures were in accordance with the guidelines established 
by University of Louisville’s Institutional Animal Care and Use Committee 
(IACUC). 
 
1. Animal sacrifice, tissue collection, and storage 
At the time of sacrifice, animals were anesthetized with ketamine/xylazine 
(100/15 mg/kg, intraperitoneally (IP)). Blood was collected before sacrifice and 
plasma was extracted by centrifugation (10,000xg for 10 minutes). Plasma was 
stored at -80 ⁰C until further analysis. Kidneys were removed and decapsulated. 
Portions of the kidney were snap-frozen in liquid nitrogen or immediately had the 
cortex separated from the rest of the kidney. The cortex was then either 
homogenized, frozen-fixed in Tissue Tek OCT-Compound (Sakura Finetek, 
Torrance, CA) or immersed in 3.7% formaldehyde in phosphate buffered saline 
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(PBS) for 24 hours followed by 70% ethanol prior to paraffin embedding for 
histology.  
 
2. Acute model of cisplatin nephrotoxicity 
Male (2-4 month old) WT C57BL/6J and C57BL6J NHERF1 (-/-) KO mice (46) 
were maintained on a 12:12 hour light-dark cycle and were provided water and 
food ad libitum. Mice received a single IP injection of 20 mg/kg cisplatin 
(University of Louisville hospital pharmacy) or vehicle (saline). Vehicle treated 
and cisplatin treated mice were euthanized after 4, 24, and 72 hours. All studies 
were performed at the same time each day. 
 
B.  Enzyme kinetics 
1. Tissue preparation 
Kidney cortex was homogenized in 0.1 M Tris-HCl, pH 7.4 on ice. Tissue 
homogenates were then sonicated on ice for 10 seconds/sample. The samples 
were then centrifuged for 15 minutes at 2,500xg at 4°C. 
 
2. Fructose-1,6-Bisphosphatase activity assay 
Solutions of 0.1 M Tris-HCl, pH 8.6; 0.1 MgCl2; 0.1 M Cysteine HCl; 50 mM 
fructose-1,6-bisphosphatase (FBPase) were prepared. All components were 
added to tissue samples, except FBPase. Blanks were then prepared for the 
assay (solution blank and sample blank in solution). Each reaction was run in a 
96 well plate with the FBPase added last to all samples and incubated for 60 
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minutes at 37°C. 10% trichloroacetic acid (TCA) was used to stop the reaction 
after the allotted time. Once a precipitate formed the plate was centrifuged at 
10,000xg for 10 minutes to lower the precipitate to the bottom of the well. 5g of 
FeSO4 was dissolved in 10 mL of 10% ammonium molybdate for working 
standards. FeSO4 working standards were prepared (0, 10, 25, 50, 100,150, 200, 
250 nM) and added to a new 96 well plate. For each sample 50 μL of the first 
reaction was then added to the new plate. Then 40 μL of the FeSO4 solution was 
added last to each standard and sample well and incubated at room temperature 
for 10 minutes. The plate was read at 10 minutes at 820 nm. (WT vehicle n=3), 
(NHERF1 KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5). 
 
3. Glucose-6-Phosphatase activity assay 
0.1 M Tris-HCl, pH 7.4; 10% TCA; 50 mM glucose-6-phosphatase (G6Pase); 
0.1M MgCl2 were prepared. Additionally, a 3.2 mM KH2PO4 solution was 
prepared and stored at 4°C. All working standards were prepared fresh using the 
3.2 mM KH2PO4 stock solution and diluted to 590 μM. Blanks were then prepared 
for the assay (solution blank and sample blank in solution). Each reaction was 
run in a 96 well plate with the G6Pase added last to all samples. The plate was 
then incubated for 60 minutes at 37°C. 10% TCA was used to stop the reaction 
after the allotted time. Once a precipitate formed the plate was centrifuged at 
10,000xg for 10 minutes to lower the precipitate to the bottom of the well. 5g of 
FeSO4 was dissolved in 10 mL of 10% ammonium molybdate for working 
standards. FeSO4 working standards were prepared (0, 10, 25, 50, 100,150, 200, 
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250 nM) and added to a new 96 well plate. Then 50 μL of the FeSO4 solution was 
added last to each standard and sample well and incubated at room temperature 
for 10 minutes. The plate was read at 10 minutes at 820 nm. (WT vehicle n=3), 
(NHERF1 KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5). 
 
4. Lactate Dehydrogenase activity assay 
0.1 M Tris-HCl, pH 7.4; 0.5 mM sodium pyruvate; 0.1M MgCl2 were prepared. 
Additionally, 0.5 mM NADH was made fresh in a 1mM sodium bicarbonate, pH 
9.0 solution the day of the reaction. Blanks were then prepared for the assay 
(solution blank and sample blank in solution). Each reaction was run in a 96 well 
plate with the NADH added last to all samples. The plate was read immediately 
after adding the NADH at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1 
KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5). 
 
5. Malate Dehydrogenase activity assay 
0.1 M Tris-HCl, pH 7.4; 0.5 mM oxaloacetate; 0.1M MgCl2 were prepared. 
Additionally, 0.5 mM NADH was made fresh in a 1mM sodium bicarbonate, pH 
9.0 solution the day of the reaction. Blanks were then prepared for the assay 
(solution blank and sample blank in solution). Each reaction was run in a 96 well 
plate with the NADH added last to all samples. The plate was read immediately 
after adding the NADH at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1 
KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5). 
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6. Malic Enzyme activity assay 
0.1 M Tris-HCl, pH 7.4; 0.5 mM L-malic acid; 0.1M MgCl2 were prepared. 
Additionally, 2mg/mL of NADP was made fresh in a 100 mM imidazole solution 
the day of the reaction. Blanks were then prepared for the assay (solution blank 
and sample blank in solution). Each reaction was run in a 96 well plate with the 
NADP added last to all samples. The plate was read immediately after adding the 
NADP at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1 KO vehicle n=4), 
(WT cisplatin n=3), (NHERF1 KO cisplatin=5). 
 
7. Glucose-6-Phosphate Dehydrogenase activity assay 
0.1 M Tris-HCl, pH 7.4; 0.5 mM glucose-6-phosphate; 0.1M MgCl2 were 
prepared. Additionally, 2mg/mL of NADP was made fresh in a 100 mM imidazole 
solution the day of the reaction. Blanks were then prepared for the assay 
(solution blank and sample blank in solution). Each reaction was run in a 96 well 
plate with the NADP added last to all samples. The plate was read immediately 
after adding the NADP at 340 nm for 3-10 minutes. (WT vehicle n=3), (NHERF1 
KO vehicle n=4), (WT cisplatin n=3), (NHERF1 KO cisplatin=5). 
 
8. γ-Glutamyl Transferase activity assay 
The activity assay was performed using the GGT colorimetric assay kit 
(Sigma Aldrich; St. Louis, Missouri) per the manufacturer’s instructions. Tissue 
samples were prepared using approximately 10 mg of kidney cortex in 200 μL of 
ice-cold GGT assay buffer. The samples were then centrifuged at 13,000xg for 
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10 minutes to remove insoluble material. The supernatant was kept and further 
diluted to 1:100 using GGT assay buffer and stored at -80°C until further use. 4 
hours: (WT vehicle: n=6), (NHERF1 KO vehicle: n=6), (WT cisplatin: n=6), and 
(NHERF1 KO cisplatin: n=6) and 24 hours: (WT vehicle: n=5), (NHERF1 KO 
vehicle: n=5), (WT cisplatin: n=7), and (NHERF1 KO cisplatin: n=8). 
 
C. Liquid Chromatography-Mass Spectrometry (LC-MS) 
1. LC-MS of kidney cortex for ATP quantification 
10 mg of kidney cortex was snap-frozen and stored in -80 °C until LC-MS 
procedure. The tissue was maintained in liquid nitrogen during preparation for 
LC-MS. Tubes and beads were pre-cooled in liquid nitrogen and 2.5% kidney 
cortex homogenate was made using an extraction solution (70% acetonitrile and 
30% H2O). Tissue was homogenized using a bead beater at 5 m/s for 15 
seconds. The homogenized tissue was then transferred to another tube for 
centrifugation at 16,000xg for 10 min at 4°C. The supernatant was saved for 
subsequent LC-MS analysis. To quantitate the ATP present in mouse kidney 
cortex tissue a standard curve was prepared using 1mM ATP diluted serially with 
the extraction buffer containing 20µM 13C10ATP. Each concentration point was 
diluted 50X with 60% ACN and 40% 15mM Ammonium Acetate. 5µL was 
injected onto a SeQuant ZIC-cHILIC 100X2.1mm metal free HPLC column.  
Separation was performed by pumping 60% ACN and 40% 15mM Ammonium 
Acetate through the column with a flow rate of 0.5mL/min with no change in 
composition using a Waters Acquity UPLC. The ATP was eluted from the column 
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and flowed into a Waters Quattro Premier XE mass spectrometer and 
subsequently quantitated using optimized MRMs. A calibration curve was 
constructed using ATP concentration on the x-axis and response of ATP over 
13C10ATP on the y axis. Mouse kidney extracts were also diluted with 50X 60% 
ACN and 40% 15mM Ammonium Acetate, 5µL was injected and the 
concentration in kidney tissue was interpolated using the calibration curve 
previously made for (WT n=5) and (NHERF1 KO n=5). 
 
D. Electron Microscopy 
1. Perfusion fixation of total kidney in situ for electron microscopy 
The abdominal cavity of the mouse was opened along the linea alba and 
intestines moved aside to expose kidneys. A suture was loosely put around the 
right kidney for removal without glutaraldehyde exposure. The right kidney was 
then used for kidney cortex homogenates. Next, the chest cavity was opened to 
expose the heart and the vena cava was cut while the right kidney was tied off 
and removed. The left mouse kidney was perfused with 3% glutaraldehyde 
solution at a rate of 6 mL/min for approximately 1-3 minutes. Perfusion was 
stopped once kidneys had a change in color and consistency. The kidney was 
removed and placed in a petri dish of 3% glutaraldehyde where three to four 0.2 
cm x 0.4 cm slices were cut and then stored in 3-4 mL of 3% glutaraldehyde at 
4°C. At this point the tissue was sent to Norton Children’s Hospital Pathology 
Department for a blinded EM analysis of kidney tubule mitochondria. Images 
were taken by a renal pathologist at the Pathology Department. Sections with the 
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highest concentration of mitochondria were randomly picked in a 4x field to be 
used to calculate mitochondria number and mitochondria area by Image J (WT 
n=6) and (NHERF1 KO n=5).  
 
E. Seahorse XF24 mitochondrial respiration analysis 
Mice for this study had food taken away 6 hours before sacrifice. 
Mitochondrial oxidative capacity was measured in isolated kidney mitochondria 
using a Seahorse Bioscience XF24 extracellular flux analyzer (Billerica, MA, 
USA). For measurements in isolated mitochondria, tissue from the kidney cortex 
of both kidneys (approximately 50 mg) was isolated and homogenized in 1 ml of 
isolation buffer (220 mM mannitol, 70 mM sucrose, 5 mM 3-(N-
morpholino)propanesulfonic acid (MOPS), 1 mM ethylene glycol tetraacetic acid 
(EGTA), 0.3% fatty acid-free bovine serum albumin (BSA), pH 7.2). The 
homogenate was centrifuged at 500 x g for five minutes at 4°C. The supernatant 
containing mitochondria was centrifuged at 10,000 x g for five minutes. Following 
two wash centrifugation steps in BSA-free isolation buffer, the mitochondria were 
suspended in respiration buffer (120 mM KCl, 25 mM sucrose, 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM MgCl2, 5 mM 
KH2PO4, pH to 7.2). Protein in the mitochondrial suspension was estimated by 
bicinchoninic acid method (Sigma) using BSA as a standard. 10 μg of 
mitochondrial protein was sedimented in XF culture plates. Succinate (10 mM), 
rotenone (1 μM), and ADP (1 mM) were injected to assess state 3 respiratory 
activity (phosphorylating respiration). The OCR of mitochondria after exposure to 
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oligomycin (1 μg/ml) was used to estimate state 4 activity (non-phosphorylating 
respiration). Finally, Antimycin A (20 μM) was stop all respiration. Data are 
expressed as pmol O2/min/μg protein (WT n=6, NHERF1 KO n=6). 
 
F. Histology and immunohistochemistry 
1. Histology 
Paraffin embedded fixed whole kidney tissue were cut in 5 μm thick either 
transversely or longitudinally from cisplatin treated and vehicle treated WT and 
NHERF1 KO animals. These sections were stained with hematoxylin and eosin 
(H&E) as well as periodic acid-schiff (PAS) to evaluate number of casts, degree 
of BBM sloughing, and ATN. These sections were sent to a pathologist for 
analysis. Images were taken at 20x and 40x (WT vehicle n=5), (NHERF1 KO 
vehicle n=5), (WT cisplatin n=7), and (NHERF1 KO cisplatin n=8). 
 
2. Immunohistochemistry (IHC) 
IHC was carried out on paraffin embedded fixed whole kidney tissue cut in 5 
μm thick sections either transversely or longitudinally from cisplatin treated and 
vehicle treated WT and NHERF1 KO animals. A primary antibody against GGT 
(1:50) (ABclonal; Woburn, MA; A1776) and 4-Hydroxynonenal (4-HNE) (1:100) 
(Abcam; Cambridge, UK; ab46545) were utilized for staining to evaluate any 
changes in proximal tubule localization or loss after cisplatin treatment. Images 
were taken at 10x, 20x and 40x (WT vehicle: n=5), (NHERF1 KO vehicle: n=5), 
(WT cisplatin: n=10), and (NHERF1 KO: n=9).  
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G. Clinical Chemistry 
1. Neutrophil gelatinase-associated lipocalin (NGAL) 
NGAL was determined using an enzyme linked immunosorbent assay 
(ELISA) kit (R&D Systems; Minneapolis, MN; DY1857) on mouse urine as 
directed by the manufacturer (WT vehicle n=5), (NHERF1 KO vehicle n=5), (WT 
cisplatin n=7), and (NHERF1 KO cisplatin n=8).  
 
H. Thiobarbituric acid reactive substances (TBARS) 
Lipid peroxidation was determined using a TBARS assay kit (Cayman 
Chemicals; Ann Arbor, MI; 10009055) on mouse kidney cortex tissue as directed 
by the manufacturer (WT vehicle n=5), (KO vehicle n=5), (WT cisplatin n=8), and 
(NHERF1 KO cisplatin n=9). 
 
I. High-performance Liquid Chromatography (HPLC) 
1. Collection of Mouse Blood and Tissue for GSH, GSSG, Cys, and Cyss  
Blood samples were collected from mice and added to a tube with 0.5 M 
borate buffer stock solution and 165 uM γ-glutamylglutamate as the internal 
standard as described in (117) within 1-2 minutes after the blood was drawn. 
Plasma was extracted via centrifugation (3,000xg for 2 minutes) and 50 uL of 
supernatant was transferred to a new tube with preservation solution (10% 
perchloric acid, 0.2 M boric acid, and 10 uM γ-glutamylglutamate). Tubes were 
then stored at -80°C. 10 mg of kidney cortex tissue was removed from the kidney 
and added to preservation solution (5% perchloric acid, 0.2 M boric acid, and 10 
 
41 
 
uM γ-glutamylglutamate) and homogenized. Kidney cortex homogenates were 
then stored at -80° until further use. Plasma: (WT vehicle: n=5), (NHERF1 KO 
vehicle: n=5), (WT cisplatin: n=7), and (NHERF1 KO cisplatin: n=9). 
 
2. HPLC Analysis of kidney cortex and plasma for GSH, GSSG, Cys, and 
CySS  
Tissue and plasma Cys, CySS, GSH and GSSG were assayed by HPLC as 
S-carboxymethyl, N-dansyl derivatives using γ-glutamylglutamate as an internal 
standard as previously described (117, 118). The HPLC system consisted of an 
aminopropyl column, 2 Waters 515 HPLC Pumps to deliver a gradient of acetate 
and methanol, a Waters 717 plus Autosampler with refrigeration unit, and a 
Waters 2475 Multi λ Fluorescence Detector. Integration of peak areas and 
comparison to internal standard was performed by Waters Empower 3 software. 
Kidney: (WT vehicle: n=5), (NHERF1 KO vehicle: n=5), (WT cisplatin: n=8), and 
(NHERF1 KO cisplatin: n=9). 
 
J. Immunoblots 
1. Western blot 
Kidney cortex homogenates were made as previously described (119). 
Protein concentration was measured by bicinchoninic acid (BCA) method 
(Sigma) using BSA as a standard. Kidney homogenates were separated by 10% 
SDS-PAGE and transferred to nitrocellulose membranes. The membranes were 
incubated with 5% (wt/vol) dried milk in Tris-buffered saline with 0.5% Tween 20 
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(TTBS) for 30 minutes to decrease nonspecific antibody binding. Membranes 
were incubated overnight at 4°C with primary antibodies against GGT (ABclonal; 
A1776) and CCBL1 (ABclonal; A6542), diluted (1:1000) in 5% milk. Membranes 
were washed with TTBS and incubated for 2 hours with horseradish peroxidase-
conjugated secondary antibodies diluted in TTBS and 5% milk. 
Chemiluminescence (ThermoScientific) was utilized to detect bands and 
visualization via GeneSys software with a Pixi imaging system (Syngene). 
Densitometric analysis was performed via Image J. For densitometric analysis, 
specific protein expression was normalized to densitometry values for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling; Beverly, 
MA) or β-actin (Cell Signaling) in each lane (WT vehicle n=3), (NHERF1 KO 
vehicle n=3), (WT cisplatin n=4), and (NHERF1 KO cisplatin n=4). 
 
L. Statistical analysis 
1. Statistical analysis of ATP, mitochondrial number, and respiration 
data 
Student’s t-test was used to evaluate LC-MS data measuring ATP content 
between WT and NHERF1 KO kidneys. Additionally, student’s t-test was used to 
compare mitochondrial number and mitochondrial respiration via Seahorse XF24 
between WT and NHERF1 KO kidney mitochondria. P-values of <0.05 were 
considered statistically significant and data were shown as mean ± standard 
error means (SEM).  
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2. Statistical analysis of enzyme kinetics, western blots, HPLC, NGAL, 
and TBARS  
Two-way analysis of variance (ANOVA) was used to evaluate changes in 
enzyme kinetics between vehicle and cisplatin treated mouse kidneys. Likewise, 
two-way ANOVA was utilized to evaluate protein expression changes in GGT 
and CCBL in treated kidney cortex by western blot; reduction/oxidation state of 
GSH and Cys in plasma and treated kidneys; lipid peroxidation by TBARS in 
treated kidneys; and urine NGAL from treated mice. P-values of <0.05 were 
considered statistically significant and data were shown as mean ± SEM.
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CHAPTER III 
 
NHERF1 LOSS RESULTS IN ALTERED PENTOSE PHOSPHATE ENZYMES IN 
MICE 
 
A. Introduction 
Although cisplatin is a widely used chemotherapeutic that treats a variety of 
solid malignant tumors (e.g. ovarian testicular, head and neck, and lung cancer), 
its mechanism of action is still not completely understood (8). Likewise, the 
mechanism of cisplatin’s nephrotoxicity remains perplexing and is surrounded by 
much controversy. Moreover, 20-30% of patients on cisplatin will develop 
cisplatin-induced AKI with a single dose (8). Currently, there are no methods of 
prevention for cisplatin-induced AKI or therapeutics to treat the development of 
AKI. Therefore, understanding patient susceptibility to cisplatin is a needed area 
of research.  
Identifying new potential biomarkers and/or therapeutic targets are a 
promising area of research. To meet this need, a new area of research has been 
proposed to involve the scaffolding protein NHERF1 and susceptibility to 
cisplatin-induced AKI (35). NHERF1 is a known monomeric intrinsic membrane 
protein that belongs to the NHERF family of PDZ-scaffold proteins (31). NHERF1 
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is found in all epithelial cells and acts as a scaffold for multi-protein signaling 
complexes. In proximal tubule cells of the kidney NHERF1 is anchored to the 
cytoskeleton in the subapical plasma membrane where it acts as a key 
scaffolding protein of transport proteins and has critical roles in defining the renal 
proximal tubule BBM composition and in regulating ion transport (31). 
Furthermore, there is increasing evidence that NHERF1 has a much broader role 
than as a scaffolding protein. In fact, NHERF1 expression and/or localization has 
been associated with tumorigenesis (33, 34). Several studies have documented 
when NHERF1 is localized at the apical membrane it acts as a tumor suppressor, 
and when its expression is lost or its localization is in the cytoplasm or nucleus it 
exhibits pro-oncogenic properties (33, 34). Additionally, NHERF1 has received 
increased interest in its involvement in a variety of functions including: cell 
structure and trafficking (38, 40), inflammatory responses (82), and tissue injury 
(35-37). One such study found that NHERF1 KO mice had attenuated cholestatic 
liver injury by bile duct ligation (36). NHERF1 loss has been reported in 
exacerbation of cisplatin-induced AKI in mice (35). Furthermore, aging rats (22 
months) exhibit a decrease in NHERF1 expression (84) associated with the 
development of renal fibrosis.  
Taken together, NHERF1 expression may also be lost in aging humans, 
predisposing these patients to cisplatin nephrotoxicity. One question addressed 
in this dissertation is whether NHERF1 loss may alter metabolic pathways 
resulting in increased sensitivity to cisplatin. Cisplatin itself is known to modify 
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renal metabolic pathways such as glycolysis, gluconeogenesis, and lipid 
metabolism in response to cellular injury and death (86, 87, 92, 93).  
 
B. Experimental Procedures 
1. Animals and treatments 
Male (2-4 month) WT and NHERF1 KO mice were treated with cisplatin (20 
mg/kg IP) for 72 hours as described in Chapter II. 
 
2. LC-MS of kidney cortex for ATP quantification 
Snap-frozen kidneys were prepared for LC-MS analysis as described in 
Chapter II. 
 
3. Enzyme kinetics 
Kidney cortex tissue was homogenized and prepared for enzyme kinetic 
assays as described in Chapter II. Enzyme kinetic assays were run for FBPase, 
G6Pase, lactate dehydrogenase (LDH), malate dehydrogenase (MDH), malic 
enzyme, and glucose-6-phosphate dehydrogenase (G6PD) as described in 
Chapter II.  
 
4. Data analysis 
Enzyme kinetic data were analyzed as described in Chapter II. 
 
5. Statistical analysis 
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Enzyme kinetic data were analyzed by two-way ANOVA as described in 
Chapter II.  
 
C. Results 
1.  Cisplatin treatment significantly decreases fructose-1,6-
bisphosphatase enzyme activity in both WT and NHERF1 KO mice. 
Previous studies investigated the effect of cisplatin on gluconeogenesis (86, 
93, 120). However, the effect of NHERF1 protein loss on gluconeogenesis before 
and after cisplatin treatment has not been investigated. The first objective of this 
dissertation was to measure the enzyme activity of FBPase before and after 
cisplatin treatment in WT and NHERF1 KO mice. FBPase is a critical regulatory 
enzyme in gluconeogenesis that catalyzes the hydrolysis of fructose-1,6-
bisphosphate to fructose-6-phosphate and inorganic phosphate (121). In order to 
determine if NHERF1 loss affected gluconeogenic enzyme activity alone or with 
cisplatin treatment, male 2-4 month old mice were treated with vehicle or cisplatin 
to induce AKI and then sacrificed after 72 hours. Kidney cortex tissue from these 
mice were used for the FBPase enzyme kinetic assay as described in Chapter II. 
There were no significant differences between vehicle [(WT: 41.5 nmole/mg 
protein/min ± 6.5) (KO: 38.7 nmole/mg protein/min ± 4.1)] or cisplatin [(WT: 20.6 
nmole/mg protein/min ± 0.4) (KO: 19.7 nmole/mg protein/min ± 1.2)] treated WT 
and NHERF KO kidneys (Figure 3.1). However, cisplatin did decrease FBPase 
activity in both WT and NHERF1 KO kidneys (P = 0.0001) (Figure 3.1). 
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Figure 3.1 
 
Figure 3.1: Effect of cisplatin treatment on fructose-1,6-bisphosphatase enzyme 
activity in WT and NHERF1 KO mouse kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin 
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described 
in Chapter II. FBPase enzyme activity was determined from kidney cortex tissue 
of these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT 
cisplatin n=3), and (KO cisplatin n=5). ***P = 0.001 cisplatin treated WT and 
NHERF1 KO mice compared to vehicle saline controls.  
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2.  Cisplatin treatment significantly decreases glucose-6-phosphatase 
enzyme activity in both WT and NHERF1 KO mice. 
G6Pase is the final step in gluconeogenesis. It hydrolyzes glucose-6-
phosphate to free glucose and a phosphate group (122). This enzyme was also 
investigated to evaluate the effect NHERF1 loss may have on gluconeogenesis 
alone or with cisplatin treatment. Kidney cortex tissue from these mice were used 
for the G6Pase enzyme kinetic assay as described in Chapter II. Similarly to 
FBPase, G6Pase activity remained comparable in WT and NHERF1 KO kidneys 
regardless of treatment [(WT vehicle: 92.3 nmole/mg protein/min ± 5.0), (KO 
vehicle: 103.0 nmole/mg protein/min ± 11.3), (WT cisplatin: 38.0 nmole/mg 
protein/min ± 5.1), and (KO cisplatin: 26.4 nmole/mg protein/min ± 3.8)], while 
cisplatin led to a significant decrease in enzyme activity in both genotypes (P 
<0.0001) (Figure 3.2). 
 
3. NHERF1 loss or cisplatin treatment does not significantly affect 
lactate dehydrogenase enzyme activity in mice. 
Lactate dehydrogenase (LDH) catalyzes the interconversion of lactate and 
pyruvate, concomitantly with the interconversion of NADH and NAD+ (123) . 
When oxygen is absent LDH converts pyruvate, the final product of glycolysis, to 
lactate (123). Kidney cortex tissue from WT and NHERF1 KO vehicle and 
cisplatin treated mice were used to evaluate enzyme activity of LDH as described 
in Chapter II. NHERF1 loss (P = 0.65) or cisplatin treatment (P = 0.71) did not  
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Figure 3.2 
 
Figure 3.2: Effect of cisplatin treatment on glucose-6-phosphatase enzyme 
activity in WT and NHERF1 KO mouse kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin 
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described 
in Chapter II. G6Pase enzyme activity was determined from kidney cortex tissue 
of these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT 
cisplatin n=3), and (KO cisplatin n=5). ***P < 0.001 cisplatin treated WT and 
NHERF1 KO mice compared to vehicle saline controls.  
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significantly affect lactate dehydrogenase activity in these mouse kidneys [(WT 
vehicle: 0.06 nmole/mg protein/min ± 0.02), (KO vehicle: 0.1 nmole/mg 
protein/min ± 0.05), (WT cisplatin: 0.1 nmole/mg protein/min ± 0.8), and (KO 
cisplatin: 0.02 nmole/mg protein/min ± 0.006)] (Figure 3.3).   
 
4. Cisplatin treatment significantly decreases malate dehydrogenase 
enzyme activity in both WT and NHERF1 KO mice. 
Malate dehydrogenase (MDH) is an enzyme involved in many metabolic 
pathways including the citric acid cycle. MDH reversibly catalyzes the oxidation 
of malate to oxaloacetate with the reduction of NAD+ to NADH (124). The effect 
of NHERF1 loss and/or cisplatin treatment on MDH activity was analyzed. In a 
similar way to LDH, NHERF1 loss or cisplatin treatment did not significantly affect 
MDH activity in these mouse kidneys [(WT vehicle: 0.9 nmole/mg protein/min ± 
0.06), (KO vehicle: 0.7 nmole/mg protein/min ± 0.02), (WT cisplatin: 0.8 
nmole/mg protein/min ± 0.02), and (KO cisplatin: 0.81 nmole/mg protein/min ± 
0.06)] (Figure 3.4).   
 
5. NHERF1 loss affects malic enzyme activity before and after cisplatin 
treatment. 
Malic enzyme (ME) catalyzes the conversion of malic acid to pyruvate and 
produces NADPH (125). ME serves as an additional source of NADPH for 
lipogenesis. In order to understand the affect that NHERF1 loss and/or cisplatin  
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Figure 3.3 
 
Figure 3.3: Lactate Dehydrogenase enzyme activity in WT and NHERF1 KO 
mouse kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin 
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described 
in Chapter II. LDH enzyme activity was determined from kidney cortex tissue of 
these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT 
cisplatin n=3), and (NHERF1 KO cisplatin n=5). No significant differences were 
recorded.  
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Figure 3.4 
 
Figure 3.4: Malate Dehydrogenase enzyme activity in WT and NHERF1 KO 
mouse kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin 
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described 
in Chapter II. MDH enzyme activity was determined from kidney cortex tissue of 
these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT 
cisplatin n=3), (NHERF1 KO cisplatin n=5). No significant differences were 
reported. 
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treatment may have on ME activity, kidney cortex tissue from vehicle or cisplatin 
treated WT and NHERF1 KO were evaluated as described in Chapter II. 
Interestingly, there was a significant genotype effect on ME activity resulting in an 
increase in activity in NHERF1 KO kidneys (P = 0.0065) (Figure 3.5). 
Additionally, a significant interaction affect was also noted between WT and 
NHERF1 KO kidneys after cisplatin treatment (P = 0.0005) [(WT vehicle: 0.07 
nmole/mg protein/min ± 0.012), (KO vehicle: 0.21 nmole/mg protein/min ± 0.01), 
(WT cisplatin: 0.15 nmole/mg protein/min ± 0.012), and (KO cisplatin: 0.13 
nmole/mg protein/min ± 0.02)] (Figure 3.5).   
 
6. NHERF1 loss affects glucose-6-phosphate dehydrogenase enzyme 
activity before and after cisplatin treatment. 
Cisplatin-induced AKI is known to decrease intermediates of the pentose 
phosphate pathway (86, 94) in mice. Glucose-6-phosphate dehydrogenase 
(G6PD) is a cytosolic enzyme that participates in the pentose phosphate 
pathway, resulting in NADPH production (126). This is accomplished when G6PD 
reduces NADP+ to NADPH while oxidizing glucose-6-phosphate (126). G6PD 
enzyme activity was analyzed in vehicle and cisplatin treated WT and NHERF1 
KO kidney cortex to elucidate if NHERF1 loss and/or cisplatin treatment affected 
the pentose phosphate pathway. Similarly to ME, there was a significant 
genotype effect on G6PD activity resulting in an increase in activity in NHERF1 
KO kidneys (P = 0.0033) (Figure 3.6). Additionally, a significant interaction affect 
was also noted between WT and NHERF1 KO kidneys after cisplatin treatment  
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Figure 3.5 
 
Figure 3.5: Effect of NHERF1 loss and cisplatin treatment on malic enzyme 
activity in WT and NHERF1 KO mouse kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin 
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described 
in Chapter II. ME activity was determined from kidney cortex tissue of these 
mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT cisplatin 
n=3), and (KO cisplatin n=5). **P = 0.0065 vehicle treated NHERF1 KO mice 
compared to WT vehicle controls; ***P = 0.0005 interaction of cisplatin treated 
NHERF1 KO mice to cisplatin treated WT mice.  
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Figure 3.6 
 
Figure 3.6: Effect of NHERF1 loss and cisplatin treatment on glucose-6-
phosphate dehydrogenase enzyme activity in WT and NHERF1 KO mouse 
kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice were given cisplatin 
(20 mg/kg dose IP) or vehicle (saline) and sacrificed after 72 hours as described 
in Chapter II. G6PD enzyme activity was determined from kidney cortex tissue of 
these mice. Data are means ± SEM (WT vehicle n=3), (KO vehicle n=4), (WT 
cisplatin n=3), and (KO cisplatin n=5). **P = 0.0065 vehicle treated NHERF1 KO 
mice compared to WT vehicle controls; **P = 0.0005 interaction of cisplatin 
treated NHERF1 KO mice to cisplatin treated WT mice. 
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 (P = 0.00029) [(WT vehicle: 0.13 nmole/mg protein/min ± 0.02), (KO vehicle: 0.3 
nmole/mg protein/min ± 0.03), (WT cisplatin: 0.3 nmole/mg protein/min ± 0.007), 
and (KO cisplatin: 0.3nmole/mg protein/min ± 0.02)] (Figure 3.6).  
 
7. NHERF1 loss does not affect amount of ATP by LC-MS in mouse 
kidneys. 
ATP provides energy to drive many cellular processes and is consumed 
during many metabolic processes (127). In eukaryotes ATP is produced by three 
different metabolic pathways: [1] glycolysis, [2] the citric acid cycle or oxidative 
phosphorylation, and [3] beta-oxidation (127). In order to determine if NHERF1 
KO kidneys had differences in ATP content, kidneys were snap-frozen and 
processed while cold for LC-MS as described in Chapter II. LC-MS analysis 
revealed that there were no significant differences in ATP amount in WT (3.4 
nmoles/mg tissue ± 0.5) and NHERF1 KO (3.1 nmoles/mg tissue ± 0.5) kidneys 
(P = 0.67) (Figure 3.7).  
 
D. Discussion 
This work had two primary goals: [1] to characterize any metabolic differences 
in NHERF1 KO mouse kidneys and [2] to evaluate if metabolic changes in 
NHERF1 KO mouse kidneys could predispose these animals to susceptibility of 
cisplatin-induced AKI. As discussed in the introduction, previous studies noted 
metabolic changes in affected mouse kidneys post cisplatin treatment, 
contributing to both injury and the development of CKD. These studies revealed 
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Figure 3.7 
 
Figure 3.7: ATP content of WT and NHERF1 KO mouse kidneys. 
2-4 month old male C57BL/6J WT and NHERF1 KO mice kidneys were removed 
and snap-frozen in liquid nitrogen. LC-MS was utilized to evaluate amount of 
ATP in these tissues as described in Chapter II. Data are means ± SEM (WT 
n=5) and (KO n=5). No significant differences were reported in these kidneys.   
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that cisplatin nephrotoxicity depletes amino acids (86-89), reduces fatty acid 
oxidation (86, 89, 91), reduces glycolytic enzymes (86, 93), and decreases 
intermediates of the pentose phosphate pathway and the citric acid cycle (86, 
94).  
One of the first objectives of this study was to evaluate any changes in 
gluconeogenesis of NHERF1 KO mouse kidneys compared to WT mouse 
kidneys pre and post cisplatin treatment. Baseline measurements of FBPase 
showed no changes in enzymatic activity with NHERF1 loss; furthermore, WT 
and NHERF1 KO kidneys both had a decrease in activity following cisplatin 
treatment. Indicating that FBPase functions similarly with or without NHERF1, 
consistent with other reports (128, 129).  Likewise, G6Pase activity was 
unchanged with NHERF1 loss and, similarly to other reports, decreased after 
cisplatin treatment in both genotypes (128, 129). These data confirm that 
NHERF1 loss does not have an apparent effect on gluconeogenesis, whereas 
cisplatin injury results in decreased gluconeogenic enzymes. MDH and LDH 
belong to the same family of NAD-dependent enzymes, and cisplatin-induced 
oxidative stress has been shown to increase LDH due to lipid peroxidation and 
decrease MDH (130, 131). Interestingly, this study found no significant changes 
in LDH and MDH activity regardless of genotype or cisplatin treatment, which is 
consistent with a previous study that demonstrated similar results where LDH 
and MDH activities were unchanged after cisplatin treatment in rats (132). These 
disparities between studies and cisplatin’s effect on LDH and MDH activities 
further illustrate the complexity of this disease. 
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ME and G6PD activity provide necessary NADPH, a key cofactor in redox 
control and reductive biosynthesis. ME plays a role in production of pyruvate and 
serves as an additional source of NADPH for lipogenesis. Mammals that utilize 
glucose for lipogenesis via citrate are believed to rely heavily on transferring 
reducing equivalents from extra-mitochondrial NADH to NADP through the 
combined acts of MDH and ME (134). Pyruvate from ME is available to re-enter 
the mitochondria and be converted to of oxaloacetate or acetyl-CoA (134). 
Additionally, there is recent evidence for direct cross-talk between ME and the 
pentose phosphate pathway (135), where G6PD is a rate limiting enzyme. 
Another goal of this study was to determine the effect of NHERF1 loss and/or the 
combined effect with cisplatin on ME and G6PD activity. Notably, both ME and 
G6PD activity were significantly increased in the NHERF1 KO mouse kidney 
under baseline conditions. Following cisplatin treatment ME and G6PD activity 
decreased until level with cisplatin treated WT activity and resulted in a 
significant interaction. These increases in ME and G6PD activity at baseline 
suggest some altered or compensatory metabolic changes in the pentose 
phosphate pathway of NHERF1 KO mice. One study found using a cell culture 
model of diabetes that increased activity of G6PD restored redox balance in 
endothelial cells exposed to high glucose levels (136), where high glucose levels 
had previously decreased G6PD and increased levels of oxidative stress. 
Multiple studies have noted the importance of cellular redox balance in both 
development of and in protection from renal injury (103, 104). In rats G6PD 
activity is reported to decrease in acute models of nephrotoxicity, and ME activity 
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is reported to increase (129). Additionally, one other investigator found that 
NHERF1 is a previously unidentified regulator of Nox1 (NADPH oxidase) and 
further promotes Nox1 activity (81). In fact, vascular smooth muscle cells 
deficient of NHERF1 were unable to mount a ROS response to potent O2 stimuli 
(81). Taken together, one possible explanation for these data are that NHERF1 
KO mice are under some stress resulting in an increase in G6PD activity in an 
attempt to restore redox balance. Whether, redox balance is indeed restored in 
these mice will be further investigated in Chapter V. These data suggest subtle 
metabolic changes in the kidneys of the NHERF1 KO animals, but do not allow 
us to make definitive conclusions on the mechanism involved. This is in part due 
to the amelioration of cisplatin nephrotoxicity when antioxidants are given or 
when there is a decrease in ROS prior to treatment. On the other hand, cisplatin 
does decrease intermediates of the pentose phosphate pathway. Indicating this 
could be a mechanism of enhanced susceptibility if the NHERF1 KO kidneys are 
more reliant on this pathway for energy generation.  
Lastly, this study evaluated ATP levels between WT and NHERF1 KO 
kidneys to determine any alterations in cellular energy. Following LC-MS 
assessment it was determined that WT and NHERF1 KO kidneys contain similar 
levels of ATP, indicating that NHERF1 KO mice are not depleted and/or 
producing higher amounts of ATP due to energy demands. Collectively, the 
results of the ATP, G6PD and ME data point towards potential changes in 
NADPH of NHERF1 KO mice. This presents another area of interest to 
investigate in the future.  
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In conclusion, this study provides insight into metabolic changes of NHERF1 
KO mice. In this study increased enzymes of the pentose phosphate pathway 
were found in NHERF1 KO mice and suggest these animals are expressing 
some differences in metabolic pathways when compared to WT animals. The 
basis for these changes in the activity of this metabolic pathway and its 
significance for the increased susceptibility of NHERF1 KO mice to cisplatin 
nephrotoxicity remain unknown. These results provide another avenue to be 
explored in the future pertaining to NADPH levels in NHERF1 KO mouse 
kidneys. Further investigation into bioenergetics of the NHERF1 KO mouse 
kidneys may elucidate more insight into susceptibility to cisplatin injury. 
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CHAPTER IV 
 
MECHANISM OF SUSCEPTIBILITY OF NHERF1 KO MICE TO CISPLATIN-
INDUCED AKI IS NOT MITOCHODNRIAL DYSFUNCTION 
 
A. Introduction 
Mitochondria are important for multiple cellular functions but are more 
commonly known as the ‘powerhouse of the cell’. In all eukaryotic cells that do 
not undergo photosynthesis the mitochondria is the main source for ATP, an 
energy rich compound that drives cellular functions (137, 138). The inner 
mitochondrial membrane is the site of the ETC and oxidative phosphorylation 
where ATP is generated from ADP and phosphate ions (137, 138). Other 
mitochondrial functions apart from cellular respiration and ATP synthesis include: 
production of NADH and GTP in the citric acid cycle, amino acid biosynthesis, 
calcium signaling, stress responses, and cellular signaling (137, 138). On the 
other hand, when mitochondria are damaged they undergo electron leakage and 
produce massive amounts of free radicals in the form of ROS, leading to cell 
injury and death. Thus, mitochondrial dysfunction is often the cause of severe 
diseases.  
Not surprisingly, the critical role of mitochondria in human health and disease 
progression has strengthened interest in the relationship of mitochondrial 
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function and cisplatin nephrotoxicity. As previously discussed in Chapters I and 
III, cisplatin is a highly successful chemotherapeutic with nephrotoxic side 
effects. This toxicity greatly limits cisplatin’s therapeutic use and often leads to 
the development of AKI (8). Pathologically cisplatin induces cell death and injury 
to the renal tubules, triggers vascular dysfunction, and launches a strong 
inflammatory response (8). These effects of cisplatin result in both necrosis and 
apoptosis in the proximal and distal tubules. Cisplatin’s mechanism of toxicity 
remains uncertain to this day, however, cisplatin induced-mitochondrial 
dysfunction and the development of renal tubule cell damage/death provides an 
attractive hypothesis.  
Cisplatin nephrotoxicity results in a decline in both state 3 mitochondrial 
respiration and calcium accumulation (139-141). Additionally, cisplatin 
nephrotoxicity has been associated with a decrease in cytochrome c oxidase 
activity and a reduction in complex IV protein expression (139-142). These 
changes can lead to increased ROS production from mitochondria. Moreover, 
cisplatin toxicity drastically reduces renal cell antioxidant activity (139, 140, 142, 
143). Some studies found that cisplatin-induced mitochondrial damage results in 
a decrease in mitochondrial mass, disruption of cristae, and even mitochondrial 
swelling (105, 139, 140). These morphological changes are associated with a 
significant reduction in mitochondrial activity and ATP production (139, 140). 
Furthermore, protein-bound platinum was found in renal tubule cell mitochondria 
24 hours after cisplatin treatment (144). Together, these studies indicate a critical 
role of mitochondrial function and oxidative stress in cisplatin nephrotoxicity. 
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These studies provided a new avenue of research to explore in understanding 
how NHERF1 loss increases susceptibility to cisplatin-induced AKI. In Chapter III 
NHERF1 loss was associated with an increase in ME and G6PD activity under 
baseline conditions and a differential response when compared to WT animals, 
suggesting compensatory mechanisms that may affect mitochondrial function. 
Previous studies from our laboratory comparing WT and NHERF1 deficient 
opossum kidney (OK) cells, a model of mammalian renal proximal tubule, 
demonstrated that the NHERF1 deficient cells grew more slowly and were more 
likely to die in culture with no apparent morphological differences. Additionally, 
proteomic studies revealed that NHERF1 KO mice exhibited markedly diminished 
associated mitochondrial proteins in the BBM of these mice (unpublished data). 
These properties of the NHERF1 deficient cells and mice (the poor survival, 
decreased expression of mitochondrial proteins in BBM, and aberrant pentose 
phosphate enzyme activity) suggested that NHERF1 loss may be associated with 
mitochondrial dysfunction and susceptibility to kidney injury. Based on these 
observations the goals of this work are twofold: [1] to determine if NHERF1 KO 
mice have altered mitochondrial function and/or structure and [2] to determine if 
NHERF1 KO mice have an underlying mitochondrial dysfunction that 
predisposes these animals to cisplatin nephrotoxicity. 
 
B. Experimental Procedures 
1. Electron microscopy 
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2-4 month old male WT and NHERF1 KO mice were perfused with 3% 
glutaraldehyde and the kidneys were removed for EM analysis as described in 
Chapter II. 
 
2. Seahorse XF24 mitochondrial respiration analysis 
Mitochondria were isolated from 2-4 month old male WT and NHERF1 KO 
mouse kidney homogenates. Seahorse XF24 analysis of OCR of isolated 
mitochondria were obtained as described in Chapter II.  
 
3. Data analysis  
EM and Seahorse XF24 mitochondrial data were analyzed as described in 
Chapter II. 
 
4. Statistical analysis 
Statistical analysis of electron microscopy and Seahorse XF24 mitochondrial 
data was performed as described in Chapter II. 
 
C. Results 
1. NHERF1 loss does not affect kidney proximal tubule mitochondria 
morphology. 
The mitochondrial structure is essential for proper function, thus, EM images 
of WT and NHERF1 KO proximal tubule mitochondria were utilized to evaluate 
their morphology as described in Chapter II. These images were taken and 
evaluated by a renal pathologist for signs of injury, oxidative stress, and changes 
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in cristae. There were no apparent changes in mitochondria morphology between 
WT and NHERF1 KO proximal tubules (Figure 4.1). The only injury reported was 
early ischemic changes mostly likely due to harvesting of the kidneys (Figure 
4.1). Some endosomal swelling was noted but occurred across both genotypes. 
Additionally, in figure 4.1 the density and distribution of mitochondria within the 
tubules were also alike. Lastly, no apparent signs of oxidative stress were found 
in either genotype (Figure 4.1).  
 
2. NHERF1 loss does not affect mitochondria number or area in kidney 
proximal tubules. 
Changes in mitochondrial number and a decrease in size have been 
associated with a decline in mitochondrial function (145). Therefore, one goal of 
this study was to determine if mitochondrial number and/or size changed in 
NHERF1 KO proximal tubules when compared to WT. Images from EM of WT 
and NHERF1 KO kidney proximal tubules were utilized in order to count the 
number of mitochondria and to calculate the average area via Image J. There 
was not a significant difference between the average number of mitochondria 
between WT and NHERF1 KO tubules (WT average number: 128.8) and 
(NHERF1 KO average number: 115) (P = 0.6) (Figure 4.2A). In addition, there 
was not a significant difference between the average area of mitochondria in WT 
and NHERF1 KO tubules (WT average area: 580,540.9 μm2) and (NHERF1 KO 
average area: 678,465.4 μm2) (P = 0.75) (Figure 4.2B).  
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Figure 4.1 
 
Figure 4.1: Electron microscopy of WT and NHERF1 KO proximal tubule 
mitochondria. 
Representative photomicrographs of a 4x field of WT and NHERF1 KO proximal 
tubule mitochondria. The left panel represents proximal tubule mitochondria of 
WT mice, while the right panel represents NHERF1 KO proximal tubule 
mitochondria (WT n=6) and (NHERF1 KO n=5). The scale bars were set at 2 μm. 
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Figure 4.2
 
Figure 4.2: Mitochondrial number and area of WT and NHERF1 KO mouse 
proximal tubules. 
2-4 month old male WT and NHERF1 KO mice were perfused with 3% 
glutaraldehyde for EM analysis. (A) Number of mitochondria were counted in 
random 4x visual fields with the highest density of mitochondria. Data are means 
± SEM (WT n=6) and (NHERF1 KO n=5). Mitochondria number of NHERF1 KO 
proximal tubules were insignificant when compared to WT. (B) Mitochondria area 
was calculated using EM images and Image J. Data are means ± SEM (WT n=6) 
and (NHERF1 KO n=5). Mitochondria area of NHERF1 KO proximal tubules were 
insignificant when compared to WT.  
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3. WT and NHERF1 KO mouse kidney mitochondria have similar 
oxidative capacities. 
The mitochondria’s capacity to reduce oxygen is a critical aspect in the 
process of mitochondrial electron transport and ATP synthesis. Therefore, 
measuring mitochondrial oxygen consumption can provide a valuable method to 
assess mitochondrial function. One purpose of this work was to assess 
mitochondrial function by oxidative capacity in WT and NHERF1 KO kidneys 
using the Seahorse XF24 analyzer. In panel A of figure 4.3 OCR of WT and 
NHERF1 KO kidney mitochondria are shown over time. Both WT and NHERF1 
KO mitochondria exhibit a similar trend and response to added substrates and 
inhibitors. When adding the substrate Succinate/Rotenone plus ADP for 
production of ATP both genotypes exhibit a maximal increase in OCR. Moreover, 
both genotypes undergo a decrease in OCR after adding Oligomycin, an inhibitor 
of Complex V (formation of ATP from ADP via O2 consumption). Lastly, 
Antimycin A shuts down all respiration, where the OCR is close to the basal 
OCR. The difference between the basal OCR and OCR after Antimycin A is the 
non-mitochondrial respiration. 
Changes in state 3 (conversion of ATP from ADP and consumption of O2) and 
state 4 (non-phosphorylating or resting respiration) respiration are commonly 
used to evaluate mitochondria oxidative capacity. Panel B of figure 4.3 shows 
both state 3 [(WT: 60 pmoles/min/μg protein ± 6) and (NHERF1 KO: 44  
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Figure 4.3 
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Figure 4.3: Mitochondrial function in isolated mitochondria of WT and NHERF1 
KO kidneys. 
Mitochondria from 2-4 month old male WT and NHERF1 KO mice were isolated 
and analyzed via the Seahorse XF24 for oxidative capacity as described in 
Chapter II. (A) OCR was recorded after the addition of both substrates 
(Succinate/Rotenone/ADP) and inhibitors (Oligomycin and Antimycin A) [(WT 
n=6) and (NHERF1 KO n =6)]. (B) State 3 and State 4 was calculated using the 
recorded OCR’s of WT and NHERF1 KO mitochondria. Data are means ± SEM 
[(WT n=6) and (NHERF1 KO n=6)]. State 3 and State 4 respiration were 
considered insignificant between WT and NHERF1 KO mouse kidney 
mitochondria. (C) Respiratory control ratio (RCR) (state 3/state 4) was calculated 
between WT and NHERF1 KO kidney mitochondria. Data are represented as 
state 3/state 4 ratio [(WT n =6) and (NHERF1 n=6)]. RCR was insignificant 
between WT and NHERF1 KO mouse kidney mitochondria.   
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pmoles/min/μg protein ± 2)] and 4 [(WT: 37 pmoles/min/μg protein ± 6) and 
(NHERF1 KO: 28 pmoles/min/μg protein ± 2)] of WT and NHERF1 KO kidney 
mitochondria, where state 3 (P = 0.2) and 4 (P = 0.1) were determined to be 
insignificant between the groups.  
The respiratory control ratio (RCR) is the best general measure of 
mitochondrial function in isolated mitochondria. RCR is measured by taking state 
3/state 4 respiration and sums up the main function of mitochondria: the ability to 
idle at low rates and then respond to ADP by making ATP at high rates. In 
addition the RCR has no absolute value that is diagnostic of mitochondrial 
dysfunction (146). Thus, RCR values are substrate and tissue dependent, 
making this complex function advantageous when measuring mitochondrial 
function in isolated mitochondria (146). A change in almost any aspect of 
oxidative phosphorylation will result in a change in the RCR when comparing 
isolated mitochondria (146). Accordingly, the RCR was calculated between WT 
(1.63) and NHERF1 (1.61) KO kidney mitochondria and also found to be 
insignificant (Figure 4.3C).  
 
D. Discussion 
The goal of this study was to determine if NHERF1 loss results in 
mitochondrial dysfunction. This possibility was investigated as a potential 
mechanism of susceptibility of NHERF1 KO mice to cisplatin-induced AKI. This is 
the first study to investigate mitochondrial dysfunction in NHERF1 KO mice, and 
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the first to show that NHERF1 KO mice do not have an underlying mitochondrial 
dysfunction. 
The morphology of proximal tubule mitochondria of WT and NHERF1 KO 
mice was determined to be similar. Structural changes in mitochondria are 
indicative of improper function thus; these observations indicate that NHERF1 
KO mice proximal tubule mitochondria do not have structural changes leading to 
dysfunction. In addition to structural changes, mitochondrial number and size 
were also evaluated. With age, mitochondrial integrity and functionality are 
known to decrease due to mutations and oxidative damage by ROS (145). 
Moreover, in aged mice (22-28 months), mitochondria exhibit lowered oxidative 
capacity, reduced oxidative phosphorylation, decreased ATP production, 
significant increase in ROS generation, and diminished antioxidant defense (145, 
147). In addition, with age mitochondrial biogenesis declines due to alterations in 
mitochondrial dynamics and inhibition of mitophagy, an autophagy process that 
removes dysfunctional mitochondria. Thus, one question postulated was if 
NHERF1 KO mice had a change in mitochondrial number and/or area that would 
indicate inadequate functioning or stress. EM analysis found that both 
mitochondrial number and area were similar between both genotypes, 
suggesting proper mitochondrial integrity and biogenesis in NHERF1 KO mice 
proximal tubules. 
Assessing mitochondrial dysfunction requires a definition of that dysfunction, 
usually defined as the mitochondria’s capability of making ATP in response to 
energy demands. Furthermore, this dysfunction can be evaluated in isolated 
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mitochondria. For isolated mitochondria the best method of evaluating 
dysfunction is analyzing mitochondrial oxidative capacity and respiratory control. 
Respiratory control is the increase in respiration in response to ADP. The RCR is 
both substrate and tissue dependent, however, when comparing different study 
groups a high RCR value indicates good mitochondrial function, while a low RCR 
indicates mitochondrial dysfunction. When comparing WT and NHERF1 KO 
mitochondrial function state 3 and state 4 were determined to be similar between 
the genotypes. Furthermore, the RCR (state 3/state 4) was determined to be the 
same (NHERF1 KO: 1.61 vs WT: 1.63). These data indicate that NHERF1 KO 
mouse kidney mitochondria are responding accordingly to energy demands when 
isolated from tissue. However, isolated mitochondria removed from their natural 
environment and the effect of the intracellular milieu on mitochondria function 
cannot be assessed in this type of assay. Previous studies established that 
NHERF1 KO mice exhibited phosphate wasting (148). This phenotype could 
create an environment where mitochondria cannot function properly. When 
isolating mitochondria both the isolation buffer and respiration buffer contain 
phosphate to ensure the isolation process does not harm the mitochondria’s 
ability to function. Therefore, a future project would be to evaluate mitochondrial 
function using whole kidney tissue with the Seahorse XF24 analyzer. This 
experiment could help clarify if NHERF1 KO mouse kidneys have an underlying 
mitochondrial dysfunction due to their environment and hence serving to answer 
the question if an underlying mitochondrial dysfunction could predispose 
NHERF1 KO mice to cisplatin nephrotoxicity. 
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This study demonstrates that proximal tubule mitochondria from NHERF1 KO 
kidneys are structurally similar and healthy when compared to WT mitochondria. 
Additionally, isolated mitochondria from NHERF1 KO mice do not exhibit 
changes in function indicative of stressed or dysfunctional kidney mitochondria. 
These data do not support the hypothesis that NHERF1 loss results in an 
underlying mitochondrial dysfunction. However, one potential mechanism that 
has yet to be investigated is whether NHERF1 loss and the subsequent low 
phosphate environment affects kidney mitochondrial function. This information 
may provide an alternative mechanism of susceptibility to cisplatin nephrotoxicity 
in NHERF1 KO mice, and it will be investigated in the future. Understanding the 
underlying mechanism of susceptibility to cisplatin-induced AKI with NHERF1 
loss may provide future therapeutic targets and or biomarkers to use in the clinic. 
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CHAPTER V 
 
NHERF1 LOSS AFFECTS GGT ACTIVITY IN RESPONSE TO CISPLATIN  
 
A. Introduction 
Cisplatin is one of the most effective chemotherapeutic agents used to treat a 
number of diseases including: head and neck, esophageal, bladder, testicular, 
ovarian, uterine, cervical, breast, stomach, small cell, and non-small cell lung 
cancer (8-10). As a chemotherapeutic cisplatin crosslinks with purine bases in 
DNA and inhibits DNA synthesis (9). Because cisplatin shows its highest activity 
in highly proliferative cells, its unusual dose-dependent and cumulative side 
effect of nephrotoxicity remains a mystery (8-10). In addition, some patients 
appear to have an increased sensitivity to this side effect, with 20-30% 
developing cisplatin-induced AKI with a single dose (8). This sensitivity remains 
an important area of research as there are no FDA-approved strategies or 
approved therapies for preventing or ameliorating cisplatin-induced AKI.  
In hopes of tackling this urgent clinical need, much research has been driven 
in understanding how cisplatin is handled by the kidneys. To date the accepted 
hypothesis for the renal handling of cisplatin is that during glomerular filtration 
cisplatin accumulates in the kidneys (149). OCT2 and Ctr1 have been identified 
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as membrane transporters capable of cisplatin uptake in renal proximal tubule 
cells (150). Furthermore, MATE1 has also been identified in transporting cisplatin 
from the proximal tubule to the urine (22). Cisplatin nephrotoxicity was 
ameliorated with OCT2 inhibition and is exacerbated with MATE1 inhibition in 
mice (18, 22, 150). Biotransformation of cisplatin is believed to start immediately 
after transportation into the apical renal epithelial cell (25). The initial 
biotransformation step is proposed to be with the formation of glutathione 
conjugates (25). These conjugates are then cleaved to cysteinyl-glycine-
conjugates by GGT, which is expressed on the surface of proximal tubule cells 
(25). From there AP is thought to convert cysteinyl-glycine-conjugates to cysteine 
conjugates, which are then believed to be further metabolized by CCBL into 
highly reactive nephrotoxic thiols (25). With that series in mind, much of the 
biotransformation of cisplatin in the kidney remains controversial. For example, it 
is known that GGT has the highest activity in the kidney and it was thus 
considered a potential target for attenuation of nephrotoxicity. However, 
investigation into that possibility yields controversial results, suggesting that 
enhanced GGT activity may either increase or decrease sensitivity to cisplatin-
induced AKI (151).  
These conflicting results have made the development of reno-protective 
strategies or therapies difficult. Recently, a new potential target, NHERF1, a 
known scaffolding protein important to the proper function of renal proximal 
tubule cells, has been identified. In this recent study NHERF1 KO mice exhibited 
exacerbated cisplatin nephrotoxicity, manifested by a significant increase in BUN, 
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NGAL, and higher histologic injury severity scores than in cisplatin treated WT 
mice (35). Interestingly, NHERF1 KO mice showed similar levels of apoptosis 
when compared to WT mice, but had a clear increase in necrotic cell death 
following cisplatin treatment (35). Other studies noted that cisplatin nephrotoxicity 
was dose dependent and involved both necrosis and apoptosis, however, higher 
levels of necrosis were associated with higher concentrations of cisplatin (152, 
153). Collectively, these data along with another study showing NHERF1 
expression was also involved with cisplatin resistance in cervical cancer cells 
(110), suggested that loss of NHERF1 may affect the renal handling of cisplatin.  
The goal of this work was to elucidate new potential mechanisms of 
susceptibility to cisplatin-induced AKI. NHERF1 loss was hypothesized to affect 
the renal handling of cisplatin by alterations in renal uptake and/or metabolism. In 
this endeavor the current understanding of cisplatin’s uptake and 
biotransformation was utilized to evaluate NHERF1’s effect on cisplatin-induced 
AKI. 
 
B. Experimental Procedures 
1. Animals and treatments 
Male (2-4 month) WT and NHERF1 KO mice were treated with cisplatin (20 
mg/kg IP) for 4, 24, or 72 hours as described in Chapter II. 
 
2. γ-Glutamyl Transferase activity assay 
The GGT activity assay was performed as described in Chapter II. 
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3. Histology and immunohistochemistry 
H&E, PAS, and IHC were performed as described in Chapter II. 
 
4. NGAL 
NGAL was determined as described in Chapter II. 
 
5. TBARS 
TBARS assay was performed as described in Chapter II. 
 
6. HPLC 
Blood and tissue samples for GSH, GSSG, Cys, CySS were processed and 
analyzed as described in Chapter II. 
 
7. Immunoblots 
Western blots were performed as described in Chapter II. 
 
8. Data analysis 
Data analysis was performed as described in Chapter II. 
 
10. Statistical analysis  
Statistical analysis was performed as described in Chapter II.  
 
C. Results 
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1. NHERF1 loss results in early cisplatin-induced renal histologic injury. 
 
H&E and PAS staining of the kidneys of cisplatin treated mice after 24 hours 
revealed that NHERF1 KO mice exhibited early histologic injury that does not 
correspond with treated WT mice at the same time point (Figure 5.1). Similarly to 
the 72 hour time point, the injury is predominantly cortical in NHERF1 KO mice at 
24 hours. This injury was manifested by intermittent casts, atrophy, and BBM 
sloughing (Figure 5.1) in NHERF1 KO mice, while cisplatin treated WT mice 
exhibited no obvious signs of histologic damage.  
 
2. Cisplatin treatment significantly increases urine NGAL protein in 
NHERF1 KO mice in comparison to cisplatin treated WT mice at 24 
hours. 
In order to confirm cisplatin treatment resulted in early higher kidney injury in 
NHERF1 KO mice urine NGAL was measured as described in Chapter II. With 
cisplatin treatment both WT (0.1 μg/mL ± 0.02) and NHERF1 KO (0.7 μg/mL ± 
0.2) mice had a significant increase in NGAL protein compared to vehicle treated 
WT (0.04 μg/mL ± 0.03) and NHERF1 KO (0.02 μg/mL ± 0.006) (P = 0.007) 
(Figure 5.2). However, a statistically significant increase in NGAL urine protein 
level was observed in cisplatin treated NHERF1 KO compared to cisplatin treated 
WT mice (P = 0.03) (Figure 5.2). Additionally, a significant decrease in NGAL 
urine protein in vehicle treated NHERF1 KO compared to vehicle treated WT 
mice was found (P = 0.04) (Figure 5.2).  
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Figure 5.1 
 
Figure 5.1: Early histologic effect of cisplatin on WT and NHERF1 KO kidneys. 
Representative photomicrographs (40x) of H&E (top panel) and PAS staining 
(bottom panel) of 24 hour cisplatin treated WT and NHERF1 KO mice. H&E 
panel (A) represents a vehicle treated WT kidney, (B) a vehicle treated NHERF1 
KO kidney, (C) a cisplatin treated WT kidney, and (D) a cisplatin treated NHERF1 
KO kidney. PAS panel (A) and (C) represent cisplatin treated WT kidneys and 
panel (B) and (D) represent cisplatin treated NHERF1 KO kidneys. Arrows 
indicate areas of injury (casts and BBM sloughing). 
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Figure 5.2 
 
Figure 5.2: Effect of cisplatin on urine NGAL. 
NGAL protein measurement of mouse urine in 24 hour cisplatin treated WT and 
NHERF1 KO mouse kidneys. Data are means ± SEM (WT vehicle: n=5), 
(NHERF1 KO vehicle: n=5), (WT cisplatin: n=7), and NHERF1 KO cisplatin: n=8). 
**P = 0.007 cisplatin treated WT and NHERF1 KO mice compared to vehicle 
saline controls; *P = 0.03 cisplatin treated NHERF1 KO compared to cisplatin 
treated WT mice; *P = 0.04 vehicle treated NHERF1 KO mice compared to 
vehicle treated WT mice. 
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3. NHERF1 loss does not affect lipid peroxidation by TBARS 
Cisplatin nephrotoxicity has been shown in rats to induce lipid peroxidation, 
oxidative degeneration on lipids in cellular membranes (120). A TBARS assay 
was utilized to test if NHERF1 loss alone led to lipid peroxidation or if cisplatin 
treated NHERF1 KO mice had an increased level of lipid peroxidation. The 
TBARS assay measures levels of malondialdehyde (MDA) and other lipid 
peroxidation products. WT and NHERF1 KO 72 hour cisplatin treated kidney 
cortex homogenates were used for this assay. Under baseline conditions lipid 
peroxidation levels were similar for both genotypes (WT vehicle: 0.95 nmole/mg 
± 0.09) and (NHERF1 KO vehicle: 0.96 nmole/mg ± 0.09) (Figure 5.3). No 
significant increase of lipid peroxidation was found with cisplatin treatment in 
either WT (0.86 nmole/mg ± 0.05) or NHERF1 KO (0.83 nmole/mg ± 0.07) mice 
(Figure 5.3). Furthermore, no differences were found between cisplatin treated 
WT and NHERF1 KO mice (Figure 5.3).  
 
4. NHERF1 loss increases 4-hydroxynonenal in cortex and 
juxtamedullary region following cisplatin treatment  
Besides MDA, 4-hydroxynonenal (4-HNE) is another product of lipid 
peroxidation. To give a broader view of lipid peroxidation in vehicle and cisplatin 
treated mice IHC of 4-HNE was performed. IHC for 4-HNE showed minimal 
staining with no marked differences between genotypes for vehicle treated 
kidneys (Figure 5.4). Cisplatin treatment resulted in an increase in 4-HNE  
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Figure 5.3 
 
Figure 5.3: Cisplatin’s effect on lipid peroxidation by TBARS in WT and NHERF1 
KO mice. 
TBARS measurement of lipid peroxidation of kidney cortex 72 hour cisplatin 
treated WT and NHERF1 KO mice. Data are means ± SEM (WT vehicle: n=5), 
(NHERF1 KO vehicle: n=5), (WT cisplatin: n=8), and NHERF1 KO cisplatin: n=9). 
No significant differences were found between treatment groups.  
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Figure 5.4 
 
Figure 5.4: The effect of NHERF1 loss and cisplatin treatment on 4-HNE staining 
in the kidney. 
Representative photomicrographs (10x) of IHC staining of 4-HNE in 72 hour 
cisplatin treated WT and NHERF1 KO mice. Panel (A) represents a vehicle 
treated WT kidney, (B) a vehicle treated NHERF1 KO kidney, (C) a cisplatin 
treated WT kidney, and (D) a cisplatin treated NHERF1 KO kidney. Arrows 
indicate areas of marked staining in the cortex and juxtamedullary (JM) region of 
the kidney.  
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staining within the cortex and juxtamedullary (JM) region of both genotypes, 
however, staining was more marked in the cisplatin treated NHERF1 KO kidneys, 
especially in the JM regions (Figure 5.4). 
 
5. NHERF1 KO kidneys do not have altered GSH metabolism 
Cisplatin nephrotoxicity is proposed to deplete GSH and to induce oxidative 
stress resulting in cellular injury and death. Due to this finding, HPLC of the 
reduced and oxidized forms of small molecular weight thiols, GSH, glutathione 
disulfide (GSSG), cysteine (Cys) and cystine (CySS), and the mixed disulfide 
between the two, cysteine-glutathione disulfide (CySSG), were performed on 
plasma and kidney cortex 72 hours after cisplatin treatment. In vehicle treated 
mice, the only significant difference observed in plasma was a CySS decrease in 
NHERF1 KO (24.1 µM ± 3.7) relative to WT (37.6 µM ± 2.7) (P = 0.0042) (Figure 
5.5 A). Additionally, after cisplatin treatment NHERF1 KO mice (18.9 µM ± 3.2) 
had a decrease in plasma CySS compared to WT (29 µM ± 4) (P = 0.0042) 
(Figure 5.5 A). In response to cisplatin, plasma CySS, Cys [(WT vehicle: 29 µM ± 
3), (NHERF1 KO vehicle: 31 µM ± 2), (WT cisplatin: 23 µM ± 3), (NHERF1 KO 
cisplatin: 20 µM ± 2)] (P = 0.013), CySSG [(WT vehicle: 22 µM ± 3), (NHERF1 
KO vehicle: 21 µM ± 6), (WT cisplatin: 16 µM ± 1), (NHERF1 KO cisplatin: 10 µM 
± 2)] (P = 0.003), GSH [(WT vehicle: 30 µM ± 3), (NHERF1 KO vehicle: 35 µM ± 
2), (WT cisplatin: 23 µM ± 2), (NHERF1 KO cisplatin: 24 µM ± 4)] (P = 0.02), and 
GSSG [(WT vehicle: 5 µM ± 1), (NHERF1 KO vehicle: 7 µM ± 2), (WT cisplatin: 3 
µM ± 0.3), (NHERF1 KO cisplatin: 3 µM ± 0.6)] (P = 0.002) decreased when  
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Figure 5.5 
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Figure 5.5: Cisplatin and NHERF1 loss effect on small molecular weight thiols. 
Plasma and Kidney GSG, GSSG, CySSG, Cys, and CySS were measured in 72 
hour vehicle and cisplatin treated WT and NHERF1 KO mice. Data are means ± 
SEM. Plasma: (WT vehicle: n=5), (NHERF1 KO vehicle: n=5), (WT cisplatin: 
n=7), and (NHERF1 KO cisplatin: n=9) and Kidney: (WT vehicle: n=5), (NHERF1 
KO vehicle: n=5), (WT cisplatin: n=8), and (NHERF1 KO cisplatin: n=9). Plasma: 
*P < 0.05 cisplatin treated WT and NHERF1 KO mice compared to vehicle saline 
controls for CySS, Cys, CySSG, GSH, GSSG, and CySSG; *P < 0.05 vehicle 
treated NHERF1 KO compared to vehicle treated WT mice for CySS. Kidney: *P 
< 0.05 vehicle treated NHERF1 KO mice compared to vehicle treated WT mice 
for CySS, Cys, and GSSG; *P < 0.05 cisplatin treated WT and NHERF1 KO mice 
compared to vehicle saline controls for CySS, Cys, CySSG, and GSSG. 
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Table 5.1: 
Oxidized and Reduced 
forms Plasma Kidney 
  
WT 
veh 
KO 
veh 
WT 
cis 
KO 
cis 
WT 
veh 
KO 
veh 
WT 
cis 
KO 
cis 
CyS ↑ ↑ ↓ ↓ ↑ ↓ ↑ ↑ 
CySS ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↑ 
CySSG ↑ ↑ ↓ ↓ ↑ ↑ ↓ ↓ 
GSH ↑ ↑ ↓ ↓ NS NS NS NS 
GSSG ↑ ↑ ↓ ↓ ↓ ↑ ↓ ↓ 
GSH/GSSG N/A N/A N/A N/A ↑ ↓ ↑ ↑ 
 
Table 5.1: Summary of the effect of NHERF1 and cisplatin on small molecular 
weight thiols.  
Plasma and Kidney GSG, GSSG, CySSG, Cys, and CySS were measured in 72 
hour vehicle and cisplatin treated WT and NHERF1 KO mice. Table 5.1 
illustrates the summarized effects of NHERF1 and cisplatin treatment on CyS, 
CySS, CySSG, GSH, GSSG, and GSH/GSSG in both the plasma and the kidney. 
N/A stands for not applicable and NS for not significant. Arrows indicate 
increased or decreased levels of each small molecular weight thiol.  
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compared to vehicle treated mice (Figure 5.5A & B). In the kidney vehicle treated 
NHERF1 KO mice had a decrease in Cys (3 nmole/mg protein ± 2) (P = 0.03) 
and an increase in GSSG (2 nmole/mg protein ± 0.1) (P = 0.022) relative to 
vehicle treated WT mice [(CySSG: 15 nmole/ mg protein ± 1), (Cys: 5 nmole/ mg 
protein ± 0.2), (GSSG: 1 nmole/mg protein ± 0.1) (Figure 5.5 C & D). Cisplatin 
treatment led to an increase in CySS [(WT cisplatin: 1 nmole/mg protein ± 0.1), 
(NHERF1 KO cisplatin: 0.8 nmole/mg protein ± 0.08)] (P = 0.002) and Cys [(WT 
cisplatin: 9 nmole/mg protein ± 1), (NHERF1 KO cisplatin : 7 nmole/mg protein ± 
0.8)] (P = 0.0005) and a decrease in CySSG [(WT cisplatin: 3 nmole/mg protein ± 
0.4), (NHERF1 KO cisplatin: 3 nmole/mg protein± 0.7)] (P < 0.0001) and GSSG 
[(WT cisplatin: 0.7 nmole/mg protein ± 0.1), (NHERF1 KO cisplatin: 0.8 nmole/mg 
protein ± 0.08)] (P  < 0.0001) in both genotypes (Figure 5.5 C & D). On the other 
hand, cisplatin did not affect the kidney levels of GSH [(WT vehicle: 30 nmole/mg 
protein ± 2), (NHERF1 KO vehicle: 27 nmole/mg protein ± 1), (WT cisplatin: 26 
nmole/mg protein ± 3), (NHERF1 KO cisplatin: 24 nmole/mg protein ± 2)] in 
either genotype (Figure 5.5 D). Kidney redox potential (GSH/GSSG) was also 
measured and found to be increased in both genotypes with cisplatin treatment 
[(WT vehicle: 26.4 ± 1.4), (NHERF1 KO vehicle: 18 ± 0.7), (WT cisplatin: 40.2 ± 
4), and (NHERF1 KO cisplatin: 29.2 ± 2)] (P = 0.0002) (Figure 5.5 E). 
Furthermore, NHERF1 KO kidneys were found to have a decrease in 
GSH/GSSG redox potential under baseline (P = 0.003) (Figure 5.5 E).  
 
6. NHERF1 loss affects GGT activity response to cisplatin insult 
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Although controversial, GGT activity is thought to be part of cisplatin’s 
biotransformation into a nephrotoxin. Urine GGT activity was found to be highest 
after cisplatin treatment at 24 hours or earlier in humans (154). To understand 
the effect NHERF1 loss has on GGT activity in response to cisplatin over time 4 
hr and 24 hr cisplatin treated WT and NHERF1 KO kidneys were evaluated. GGT 
activity was found to be non-significantly altered with NHERF1 loss alone at any 
timepoint [4hr (WT vehicle: 5800 nmole/min/mL ± 1300), (NHERF1 KO vehicle: 
5700 nmole/min/mL ± 1600)] and [24 hr (WT vehicle: 8100 nmole/min/mL ± 
2300), (NHERF1 KO vehicle: 7200 nmole/min/mL ± 1500)], and remained similar 
4 hours after cisplatin treatment [4 hr (WT cisplatin: 7000 nmole/min/mL ± 1600), 
(NHERF1 KO cisplatin: 5300 nmole/min/mL ± 1600)] (Figure 5.6). However, 24 
hours after cisplatin treatment there was a significant genotype difference 
between WT and NHERF1 KO kidneys in response to cisplatin [24 hr (WT 
cisplatin: 9900 nmole/min/mL ± 2400), (NHERF1 KO cisplatin: 7300 
nmole/min/mL ± 1400)] (P = 0.04) (Figure 5.6).  
 
7. NHERF1 loss does not affect GGT protein expression 
To evaluate if NHERF1 loss affected the amount of GGT protein a western 
blot was performed on the 4 and 24 hour cisplatin treated WT and NHERF1 KO 
kidney homogenates (Figure 5.7). GGT protein expression was found to be 
unchanged with NHERF1 loss under baseline conditions for either time point [4 
hr (WT vehicle: 0.84 GGT/GAPDH ± 0.05), (NHERF1 KO vehicle: 0.62 
GGT/GAPDH ± 0.08)] and  
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Figure 5.6 
 
 
Figure 5.6: Effect of NHERF1 on GGT activity following cisplatin treatment. 
GGT activity was measured at 4 hours and 24 hours after cisplatin treatment in 
WT and NHERF1 KO kidney cortex homogenates as described in Chapter II. 
Data are means ± SEM. 4 hours: (WT vehicle: n=6), (NHERF1 KO vehicle: n=6), 
(WT cisplatin: n=6), and (NHERF1 KO cisplatin: n=6) and 24 hours: (WT vehicle: 
n=5), (NHERF1 KO vehicle: n=5), (WT cisplatin: n=7), and (NHERF1 KO 
cisplatin: n=8). *P < 0.04 cisplatin treated NHERF1 KO compared to cisplatin 
treated WT.   
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Figure 5.7 
 
 
Figure 5.7: Effect of NHERF1 loss on GGT protein. 
Representative blots of 4 hour (A) and 24 hour (B) GGT and GAPDH are shown. 
Kidney cortex homogenates were separated by 10% SDS-PAGE and transferred 
to nitrocellulose membranes. Quantitation was performed as described in 
Chapter II (B) Data are means ± SEM (WT vehicle: n=3), (NHERF1 vehicle: n=3), 
(WT cisplatin: n=4), and (NHERF1 KO cisplatin: n=4). A representative blot from 
2 independent experiments for each time point is shown. 
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[24 hr (WT vehicle: 1.3 GGT/GAPDH ± 0.14), (NHERF1 KO vehicle: 1.2 
GGT/GAPDH ± 0.1)] (Figure 5.7).Following cisplatin the amount of GGT protein 
was also found to be unchanged at 4 and 24 hours post treatment in both 
genotypes [4 hr (WT cisplatin: 0.7 GGT/GAPDH ± 0.09), (NHERF1 KO cisplatin: 
0.9 GGT/GAPDH ± 0.03)] and [24 hr (WT cisplatin: 1.2 GGT/GAPDH ± 0.13), 
(NHERF1 KO vehicle: 0.9 GGT/GAPDH ± 0.2)] (Figure 5.7). 
 
8. GGT localization is altered in NHERF1 KO kidneys 24 hours after 
cisplatin treatment 
To evaluate localization of GGT in WT and NHERF1 KO kidneys, kidney 
slices were stained for GGT by IHC. IHC revealed similar GGT staining in the 
proximal tubules of both vehicle treated genotypes (Figure 5.8, panel A & B). In 
cisplatin treated WT kidneys there was no apparent damage and GGT 
localization remained unaltered (Figure 5.8, panel C). However, in the cisplatin 
treated NHERF1 KO kidneys areas of BBM sloughing in the proximal tubule 
showed decreased staining for GGT (Figure 5.8, panel D).  
 
9. NHERF1 loss does not affect CCBL protein 
CCBL is a pyridoxal phosphate-dependent enzyme that metabolizes S-
cysteine conjugates through transamination or β-elimination reactions, and is 
also proposed to be involved in cisplatin’s biotransformation into a nephrotoxin. 
To determine if there were any changes in CCBL protein in WT and NHERF1 KO 
mice 4 hour and 24 hour cisplatin treated kidney cortex  
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Figure 5.8 
 
 
Figure 5.8: GGT localization in vehicle and cisplatin treated kidneys. 
Representative photomicrographs (40x) of IHC staining of GGT in 24 hour 
cisplatin treated WT and NHERF1 KO mice. Panel (A) represents a vehicle 
treated WT kidney, (B) a vehicle treated NHERF1 KO kidney, (C) a cisplatin 
treated WT kidney, and (D) a cisplatin treated NHERF1 KO kidney. Arrows 
indicate areas of BBM sloughing and GGT staining loss.  
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homogenates were analyzed via western blot. CCBL protein was found to be 
unchanged with NHERF1 loss under baseline conditions for either time point [4 
hr (WT vehicle: 1.4 CCBL/GAPDH ± 0.3), (NHERF1 KO vehicle: 1.1 
CCBL/GAPDH ± .01)] and [24 hr (WT vehicle: 2.5 CCBL/GAPDH ± 0.7), 
(NHERF1 KO vehicle: 1.2 CCBL/GAPDH ± 0.1)] (Figure 5.9). Following cisplatin 
the amount of CCBL protein was also found to be unchanged at 4 and 24 hours 
post treatment in both genotypes [4 hr (WT cisplatin: 1.7 CCBL/GAPDH ± 0.1), 
(NHERF1 KO cisplatin: 1.3 CCBL/GAPDH ± 0.2)] and [24 hr (WT cisplatin: 2.2 
CCBL/GAPDH ± 0.4), (NHERF1 KO cisplatin: 2.4 CCBL/GAPDH ± 0.8)] (Figure 
5.9).  
 
D. Discussion  
The purpose of this study was to determine if NHERF1 loss affected the renal 
handling of cisplatin. This possibility was investigated as a potential mechanism 
of susceptibility of NHERF1 KO mice to cisplatin-induced AKI. This is the first 
study to investigate the effect NHERF1 loss has on cisplatin uptake and/or 
metabolism in the kidney as well as the first study to show an altered GGT 
activity in response to cisplatin in NHERF1 KO mice. 
NHERF1 KO mice are indeed more sensitive to cisplatin as confirmed by 
earlier signs of cisplatin related kidney injury. WT mice did not show histologic 
signs of injury 24 hours after cisplatin treatment. Additionally, WT mice had a 
moderate increase in urine NGAL, a sensitive marker of kidney injury, 24 hours 
after treatment. On the other hand, NHERF1 KO mice showed patchy areas of  
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Figure 5.9 
 
Figure 5.9: Effect of NHERF1 loss on CCBL protein. 
Representative blots of 4 hour (A) and 24 hour (B) CCBL and GAPDH are 
shown. Kidney cortex homogenates were separated by 10% SDS-PAGE and 
transferred to nitrocellulose membranes. Quantitation was performed as 
described in Chapter II (B) Data are means ± SEM (WT vehicle: n=3), (NHERF1 
vehicle: n=3), (WT cisplatin: n=4), and (NHERF1 KO cisplatin: n=4). A 
representative blot from 2 independent experiments for each time point is shown. 
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histologic injury 24 hours after cisplatin administration (e.g. BBM sloughing, 
casts, and atrophy). Moreover, NHERF1 KO mice had a robust increase in urine 
NGAL 24 hours following cisplatin treatment. These data corroborate the 
increased sensitivity to cisplatin seen in the previous 72 hour study (35). In 
addition to evaluating the sensitivity of NHERF1 KO mice to cisplatin, levels of 
lipid peroxidation were also measured. 
Cisplatin has been shown to increase lipid peroxidation due to induced 
oxidative stress. In this study a TBARS assay was utilized and WT and NHERF1 
KO mice were found to have similar levels of lipid peroxidation via MDA. These 
data illustrate the perplexing nature of cisplatin nephrotoxicity, where much of the 
research is contradictory. In this study kidney cortex was used for the sample 
preparation, however, other studies used whole kidney or did not clarify whether 
cortex was isolated (155, 156). Conceivably these conflicting results may be due 
to what area of the kidney was used, especially since IHC of 4-HNE revealed that 
NHERF1 KO mice had an increased positive staining in both cortex and the JM 
region. On the other hand, many of the lipid peroxidation studies were performed 
on rats, while studies on mice seem to be dependent on the concentration of 
cisplatin, dosing regimen, and mouse strain (116, 156, 157). In addition, rats are 
more sensitive to cisplatin nephrotoxicity than mice (116). Thus, cisplatin 
nephrotoxic cell death and the relationship to induced lipid peroxidation remains 
obscure. However, both the TBARS assay and the IHC data reinforce that 
NHERF1 KO mice do not have an underlying increase in lipid peroxidation. 
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Therefore, this is not a mechanism of susceptibility of NHERF1 KO mice to 
cisplatin-induced AKI. 
Even though there was no apparent increase in lipid peroxidation other 
indicators of oxidative stress were measured. These indicators included the 
oxidized and reduced forms of small molecular weight thiols that act as 
antioxidants. Plasma from 72 hour cisplatin treated mice showed a consistent 
decrease in GSH, GSSG, CySSG, Cys, and CySS. These data are consistent 
with other reports (25, 158-160). When compared to WT alone, NHERF1 loss led 
to a decrease in cystine (CySS), which is the oxidized form of cysteine. CySS is 
readily taken up into cells to be reduced to Cys. Cys is a necessary substrate for 
the cellular antioxidant GSH (161). Although plasma CySS is decreased in the 
vehicle treated NHERF1 KO mice GSH in the kidney remains similar between 
vehicle treated WT and NHERF1 KO mice. Like in other studies, the kidney 
CySSG and GSSG are decreased in both genotypes with cisplatin treatment, but, 
unexpectedly GSH was not decreased in either genotype (159). The oxidized 
form of glutathione (GSSG), was increased in the kidney of vehicle treated 
NHERF1 KO mice. Collectively, NHERF1 KO mice had a decrease in CySS in 
the plasma and an increase in GSSG in the kidney. Moreover, NHERF1 KO mice 
had a decrease in kidney redox potential (GSH/GSSG) when compared to WT. 
Perhaps these data indicate a low level of oxidative stress or maybe a 
suppressed ability to convert CySS to Cys and GSSG to GSH with NHERF1 loss. 
However, NHERF1 KO kidneys do not reflect a decrease in GSH levels. 
Therefore, it appears that NHERF1 loss does not affect GSH metabolism itself. 
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Unfortunately, the role of NHERF1 loss and an underlying oxidative stress 
remains ambiguous as a potential mechanism. In the future measuring 
glutathione peroxidase, glutathione synthase, superoxide dismutase or catalase 
in WT and NHERF1 KO mice may be beneficial.  
In addition to GSH metabolism and oxidative stress indicators, GGT activity 
was also measured. Several studies have indicated GGT activity and/or 
expression is important to the biotransformation of cisplatin to a nephrotoxin (13, 
25, 26). A robust increase in GGT activity was seen in the 24 hour cisplatin 
treated WT mice, while an increase in GGT activity was not seen in the NHERF1 
KO mice, making it appear that they are unable to respond to cisplatin in this 
manner and suggesting that NHERF1 is important for GGT’s response to an 
insult. The role of GGT activity or expression in protection or susceptibility to 
cisplatin nephrotoxicity is also controversial (113, 151). GGT KO mice are 
protected from cisplatin nephrotoxicity (112). Alternatively, depending on the cell 
type an increase in GGT activity may be protective or increase sensitivity to the 
drug (151, 162). These data have led to two alternative theories: [1] GGT is 
important in the conversion of cisplatin to a nephrotoxin thus inhibition leads to 
protection or [2] GGT is important for detoxification of xenobiotics and production 
of GSH, thus increased activity results in increased GSH production that can 
alleviate some of the induced oxidative stress from cisplatin. The second theory 
may explain the exacerbated AKI in NHERF1 KO mice. If NHERF1 loss limits the 
ability of GGT to respond quickly and/or robustly to an insult there may be 
increased injury. Besides evaluating GGT activity, protein levels and localization 
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were investigated. GGT protein levels were not significantly different, however, 
IHC showed some GGT loss in the proximal tubule due to BBM sloughing. This 
GGT loss has been recorded in mice treated with cisplatin for 72 hours in 
addition to a decrease in GGT activity at 72 hours (116, 154, 163). This 
observation provides an alternative hypothesis for the difference in GGT activity 
between WT and NHERF1 KO mice. Because NHERF1 KO mice are beginning 
to lose GGT through BBM sloughing perhaps this is affecting their level of GGT 
activity in response to cisplatin. Alternatively, a 12 hour time point may be useful 
to determine if NHERF1 KO mice have an increase in activity between 4 and 24 
hours post cisplatin treatment. This proposal would fall under the hypothesis that 
an increase in GGT activity leads to worse injury. Thus, NHERF1 KO mice could 
have an increase in GGT activity earlier and subsequently result in increased 
damage by 24 hours. In any case more research is needed to understand how 
cisplatin causes nephrotoxicity and what role GGT plays in that mechanism. 
CCBL is the rate limiting enzyme in the production of the ‘reactive thiol’ in 
cisplatin nephrotoxicity (13, 25-27). Understanding the effect of NHERF1 loss on 
CCBL protein level, localization, and activity level are valuable pieces of 
information. In this work CCBL protein level was investigated and found to be 
similar regardless of genotype or treatment. Future experiments will also 
evaluate CCBL activity and localization between vehicle and cisplatin treated WT 
and NHERF1 KO mice. In addition to CCBL, determining platinum (Pt) levels in 
cisplatin treated WT and NHERF1 KO mice is imperative. A change in Pt levels 
between cisplatin treated WT and NHERF1 KO mice would be indicative of either 
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altered uptake or extrusion of cisplatin. Blocking of the extrusion transport 
protein, MATE1, results in increased toxicity from cisplatin (22). Moreover, 
increased uptake and increased cisplatin concentrations led to worse damage 
and an increase in necrosis (28, 116). Previously, 72 hour cisplatin treated 
NHERF1 KO mice had an increase in ATN when compared to treated WT mice 
(35). Thus, these data could suggest higher levels of cisplatin in these kidneys. 
72 hour and 24 hour cisplatin treated kidneys have been sent for ICP-MS 
analysis for Pt levels. This future data could provide more insight into the 
exacerbated AKI of NHERF1 KO mice. 
Ultimately, the mechanism of cisplatin nephrotoxicity remains a mystery, 
however, it is evident that NHERF1 expression has a vital role in its 
development. Until the other areas discussed (CCBL localization, activity, and Pt 
levels) have been investigated the underlying mechanism of susceptibility to 
cisplatin in NHERF1 KO mice remains unclear. These future experiments are 
integral in elucidating the mechanism of susceptibility. Continued research and 
broadening the understanding of cisplatin nephrotoxicity and susceptibility is an 
encouraging area for the development of new innovative preventative protocols 
or even therapeutic targets that can be used in the clinic. 
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CHAPTER VI 
 
DISCUSSION AND CONCLUSIONS 
 
A. Restatement of goals and questions 
The overall goal of the work described in this dissertation was to discover new 
potential mechanisms and hypotheses for susceptibility to cisplatin-induced AKI 
with NHERF1 loss. The work summarized in Chapter III aimed to test if metabolic 
changes played a role in the sensitization of the NHERF1 KO mouse kidney to 
cisplatin insult. Chapter IV aimed to evaluate if NHERF1 KO mice had an 
underlying mitochondrial dysfunction due to: [1] decreases in mitochondrial 
oxidative capacity and/or alterations in the structure of NHERF1 KO kidneys [2] 
decreases in number of mitochondria in NHERF1 KO kidneys. Finally, Chapter V 
of this dissertation used the proposed mechanism of cisplatin biotransformation 
to a nephrotoxin to test if NHERF1 loss resulted in altered renal handling of 
cisplatin. Taken together, these studies provide new insight into the mechanism 
of susceptibility of NHERF1 loss in cisplatin-induced AKI.   
 
B. Major findings of this dissertation 
1. NHERF1 loss results in altered pentose phosphate enzymes in mice
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The accumulation and bioactivation of cisplatin to a nephrotoxic metabolite 
has been extensively studied, but requires further clarification for the 
development of novel therapeutic targets or prevention protocols to be used in 
the clinic. Recent studies have found that cisplatin alters renal cell metabolism, 
contributing to injury and the secondary result of CKD development. These 
studies have provided a new avenue of research for cisplatin-induced AKI 
development. Cisplatin treatment results in depletion of amino acids in the kidney 
(86-89), reduces fatty acid oxidation while concomitantly accumulating fatty acids 
in the kidney (86, 89, 91), and decreases renal glycolytic enzymes and 
intermediates of the pentose phosphate pathway (86, 93). These observations 
combined with the increased susceptibility to cisplatin-induced AKI suggested the 
hypothesis that NHERF1 KO mice have metabolic alterations that predispose 
them to cisplatin nephrotoxicity. Therefore, the goal of Chapter III was to define 
metabolic changes in the NHERF1 KO mouse. Overall this study uncovered new 
areas to investigate in understanding susceptibility to cisplatin-induced AKI with 
NHERF1 loss.  
NHERF1 KO mice did not exhibit changes in gluconeogenic or glycolytic 
enzyme activity. Indeed, cisplatin treatment resulted in a parallel decrease in 
FBPase and G6Pase activity in NHERF1 KO and WT mice. Additionally, there 
were no significant changes with LDH and MDH activity between non-treated and 
treated WT and NHERF1 KO mice. These results coincide with previous studies 
(86, 94). NHERF1 KO mice also do not have changes in kidney ATP content 
when compared to WT. On the other hand, NHERF1 KO mouse kidneys exhibit 
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increased activity of ME and G6PD under baseline conditions when compared to 
WT mouse kidneys. Cisplatin treatment resulted in a decrease in G6PD and ME 
activity in the NHERF1 KO kidneys that was equivalent to the level of cisplatin 
treated WT kidneys. These findings suggest that NHERF1 KO mice have 
developed compensatory mechanisms involving the pentose phosphate pathway 
and in NADPH production in order to maintain the cellular redox state. A similar 
observation has been made in studies of liver cirrhosis in rats subject to oxidative 
stress, where an increase in ME and G6PD gene expression and activity (164) 
are also seen, presumably providing protection against the stress through an 
increased production of NADPH (164).  
These observations bring into question whether NHERF1 KO mice are under 
oxidative stress that is masked due to increased NADPH. Therefore, when these 
mice are given cisplatin, a known oxidative stress inducer, the mouse kidneys 
undergo more severe damage due to the inability to combat the additional 
underlying oxidative stress following cisplatin treatment. This work has revealed 
new areas to investigate and laid the foundation for future studies, such as 
investigating NADPH levels and gene and protein expression of ME and G6PD 
between WT and NHERF1 KO mice.  
 
2. Mechanism of susceptibility of NHERF1 KO mice to cisplatin-induced 
AKI is not mitochondrial dysfunction 
Chapter IV of this dissertation aimed to characterize any differences in 
mitochondrial function and/or structure between WT and NHERF1 KO mice. This 
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aim builds upon the work described in Chapter III of this dissertation, which 
demonstrated that NHERF1 KO mice do not have gluconeogenic or glycolytic 
enzyme activity alterations, but do have increased pentose phosphate enzyme 
activity. In addition to affecting metabolic pathways cisplatin nephrotoxicity has 
been established in inducing apoptotic and necrotic cell death. The mechanisms 
involved in cisplatin-induced nephrotoxic cell death remain unclear. However, 
there is increasing evidence that ROS and mitochondrial function have an 
important role in cisplatin’s mechanism of injury. As discussed in Chapter III, 
NHERF1 KO mice may have increased levels of NADPH to maintain cellular 
redox levels, therefore the results from Chapter III and previous studies from our 
laboratory (poor survival of NHERF1 deficient OK cells and decreased 
expression of mitochondrial BBM proteins in NHERF1 KO mice) suggested the 
hypothesis that NHERF1 loss may be associated with mitochondrial dysfunction 
and susceptibility to kidney injury.  
In Chapter IV there were two main goals in characterizing differences in 
mitochondria between WT and NHERF1 KO mice: [1] to determine if NHERF1 
KO mice have altered mitochondrial function and/or structure and [2] to 
determine NHERF1 KO mice have an underlying mitochondrial dysfunction and if 
that predisposes these animals to cisplatin nephrotoxicity. EM analysis revealed 
that NHERF1 KO mice have similar proximal tubule mitochondrial morphologies, 
size, and distribution and number when compared to WT. Furthermore, there 
were no overt signs of oxidative stress in NHERF1 KO mitochondria. In fact, only 
early ischemic changes most likely due to harvesting were noted. In addition, 
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isolated mitochondria from NHERF1 KO kidneys were found to have similar 
oxidative capacities as demonstrated by nonsignificant changes in OCR and 
similar RCR (WT: 1.63 and KO: 1.61) (Figure 4.3C) to those of WT mice. The 
RCR data is compelling since this is the best general measure of mitochondrial 
function in isolated mitochondria. RCR gives an idea into the mitochondria’s 
ability to respond robustly to the addition of substrate and ADP through the 
production of ATP. In addition, the RCR value is unique to each tissue and 
substrate used (146). Therefore, NHERF1 KO mitochondria when isolated from 
their environment function normally. This study answers an important aspect in 
evaluating NHERF1 KO mitochondria which is that they can function normally 
when given optimal components. However, this poses the question if NHERF1 
KO mitochondria function normally in their natural environment. NHERF1 KO 
mice undergo phosphate wasting (148) potentially creating an intracellular 
environment where mitochondria cannot function properly. This work uncovers a 
novel potential mechanism of susceptibility to cisplatin-induced AKI that can be 
investigated in future studies. Seahorse XF24 analysis on kidney tissue would be 
beneficial in establishing if NHERF1 KO mice have mitochondrial dysfunction due 
to phosphate wasting that sensitizes the kidney to cisplatin toxicity.  
 
3. NHERF1 loss affects GGT activity in response to cisplatin 
The studies in Chapter III and Chapter IV focus on potential underlying 
changes that could increase susceptibility to cisplatin nephrotoxicity. Therefore, 
Chapter V focused on the renal handling of cisplatin between WT and NHERF1 
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KO mice. This study was based on the hypothesis that NHERF1 loss results in 
altered renal uptake and/or metabolism of cisplatin resulting in increased toxicity. 
Understanding the renal handling of cisplatin is an important area of research 
that has been substantially investigated. Unfortunately, many aspects of 
cisplatin’s metabolism to a nephrotoxin remain ambiguous with conflicting results. 
For example, the role of GGT activity in cisplatin nephrotoxicity is controversial, 
where enhanced GGT activity may either increase or decrease sensitivity to 
cisplatin-induced AKI (151). Furthermore, in the proposed hypothesis of 
cisplatin’s biotransformation to a nephrotoxin, cisplatin is thought to exit the 
proximal tubule via MATE1 where it is further processed in the tubular lumen and 
taken up in the proximal tubule by an unknown transport protein. Thus, the 
conflicting data along with potentially other unknown players add a degree of 
complexity in understanding cisplatin-induced AKI.  
Before investigating changes in renal handling of cisplatin, Chapter V first set 
to establish that NHERF1 KO mice are indeed more sensitive to the initial 
cisplatin insult. Therefore, WT and NHERF1 KO mice were treated with cisplatin 
for 24 hours instead of 72 hours. These kidneys were processed for histology 
and markers of kidney injury. Ultimately, NHERF1 KO mouse kidneys were 
confirmed to be more sensitive to the initial insult, characterized by early 
histologic changes (casts and BBM sloughing) along with significantly increased 
urine NGAL protein when compared to cisplatin treated WT.  
Next, levels of lipid peroxidation were assessed by the means of TBARS 
analysis and IHC of 4-HNE between vehicle and cisplatin treated WT and 
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NHERF1 KO mice. Some studies have shown that cisplatin induces lipid 
peroxidation, and are thought to be involved in ROS induced cell death (165). 
NHERF1 KO mouse kidneys were found to not have increased levels of lipid 
peroxidation under baseline conditions, however, with cisplatin treatment IHC 
analysis revealed increased positive staining for 4-HNE in the cortex and the JM 
regions of the kidney. Even though there was no apparent increase in lipid 
peroxidation other indicators of oxidative stress were measured. These indicators 
included the oxidized and reduced forms of small molecular weight thiols that act 
as antioxidants. Plasma from 72 hour cisplatin treated mice showed a decrease 
in all reduced and oxidized forms of glutathione and cysteine which is consistent 
with other reports (25, 158-160). The only difference noted between NHERF1 KO 
mouse plasma and WT alone was a decrease in the oxidized form of cysteine, 
CySS. CySS is necessary for the production of the cellular antioxidant GSH 
(161). Interestingly, the kidney GSH levels of NHERF1 KO mice do not reflect the 
decrease in plasma CySS. The decrease in CySSG and GSSG in the kidney 
after cisplatin administration are consistent with other reports, however GSH 
was, unexpectedly, not decreased in either genotype (159). Furthermore, the 
oxidized form of glutathione, GSSG, was increased in the kidneys of vehicle 
treated NHERF1 KO mice. In summary, NHERF1 KO mice had a decrease in 
oxidized cysteine in the plasma, an increase in oxidized glutathione in the kidney, 
and a decrease in kidney redox potential (GSH/GSSG) when compared to WT. 
These results may indicate that NHERF1 KO kidneys are under a level of 
oxidative stress and support the findings in Chapter III, where the pentose 
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phosphate enzymes may be increased to compensate with a higher NADPH 
production to maintain cellular redox levels. On the other hand, NHERF1 KO 
kidneys do not have a decrease in GSH levels and appear to not have changes 
in GSH metabolism itself. 
Lastly, enzymes thought to be involved in cisplatin’s mechanism to a reactive 
thiol were considered. GGT activity in the urine was found to be highest between 
4 and 24 hours following cisplatin treatment in humans (154), indicating these 
time points should be used in assessing differences in activity level. At 4 hours 
GGT activity remained unvarying between the treatment groups. However, at 24 
hours WT mouse kidneys responded to cisplatin treatment with a substantial 
increase in activity while NHERF1 KO kidneys maintained a steady activity level. 
These data indicate that NHERF1 KO mice respond differently to the cisplatin 
insult. Whether this response is time dependent or based on functional ability of 
the enzyme is unclear. A 12 hour time point may be helpful to further elucidate 
the changes in GGT activity in treated NHERF1 KO mice. Interestingly, GGT 
protein levels were unchanged between the treatment groups via western blot. 
IHC was also performed on NHERF1 KO and WT kidneys resulting in similar 
staining intensity and localization of GGT within the tubules under baseline 
conditions. However, 24 hours after cisplatin treatment NHERF1 KO kidneys 
began to show some histologic changes including BBM sloughing which 
coincided with decreased staining for GGT. These data are consistent with other 
studies performed on rats at 72 hours, where increased damage to the proximal 
tubule coincided with decreased GGT expression and activity (116, 154, 163). 
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Although NHERF1 KO kidney GGT protein expression remained insignificant 
with cisplatin treatment it is apparent that the degree of injury at 24 hours is less 
than what is seen at 72 hours. It is possible that NHERF1 KO mouse kidneys are 
beginning to lose GGT at 24 hours through BBM sloughing, but have not lost a 
significant amount of GGT protein at this time point. These experiments could be 
repeated on 72 hour cisplatin treated mice for improved interpretation of these 
results. CCBL protein was also measured in these mice. Similar to the GGT 
western blot data CCBL protein remained insignificantly altered between the 
different groups.  
This study has provided some clarification regarding changes in the renal 
handling of cisplatin with NHERF1 loss. The main finding being an altered 
response in GGT activity with the cisplatin insult. Furthermore, this study 
confirmed that NHERF1 KO mice are indeed more sensitive to the cisplatin 
insult. NHERF1 KO mice do not have overt signs of oxidative stress, but this may 
be masked by compensatory mechanisms in the pentose phosphate pathway. 
Most importantly, this study has laid the groundwork for future experiments 
regarding altered renal handling of cisplatin in the NHERF1 KO mouse. A few 
examples include: implementing a 12 hour time point to study time dependent 
changes in GGT activity following cisplatin treatment, CCBL activity and 
localization, and evaluating GGT and CCBL localization and protein levels 72 
hours after cisplatin treatment.  
 
C. Significance of new findings 
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Chapter III investigated metabolic changes in NHERF1 KO mice that may 
predispose these animals to cisplatin nephrotoxicity. Moreover, gluconeogenic 
and glycolytic enzymes were found to be unchanged, but ME and G6PD had 
increased activities with NHERF1 loss. The significance of these findings is that 
that NHERF1 KO mice may have compensatory mechanisms in the NADPH-
dependent processes for maintenance of the cellular redox state. G6PD and ME 
are the two main sources of cytosolic NADPH, which is important for protection 
from oxidative stress (166). Furthermore, G6PD activity through the generation of 
ribose-5-phosphate is also involved in nucleic acid synthesis and repair (164). 
Therefore, enhancement of ME and G6PD is consistent with the presence of 
some underlying stress in the NHERF1 KO mouse. The combined effect of an 
underlying oxidative stress and the cisplatin-induced oxidative stress could result 
in increased sensitivity and exacerbation of injury with NHERF1 loss. 
The work in Chapter IV involved characterizing differences in mitochondrial 
structure and/or function between WT and NHERF1 KO kidneys. Interestingly, no 
changes in mitochondrial structure, number or size were found to indicate an 
altered function or mitochondrial oxidative stress. Furthermore, Seahorse XF24 
functional assays determined that isolated NHERF1 mitochondria function 
normally when compared to WT. This observation suggests that NHERF1 KO 
mitochondria have normal bioenergetics when all required compounds are 
available. However, NHERF1 KO mice do undergo phosphate wasting (148), 
potentially creating a suboptimal intracellular environment for mitochondria. 
Inorganic phosphate is essential for many cellular functions such as signal 
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transduction and energy metabolism. For instance, inorganic phosphate uptake 
into mitochondria is required for oxidative phosphorylation and the subsequent 
production of ATP (167). Mitochondrial inorganic phosphate also activates matrix 
enzymes and ETC activity (167). Moreover, in insulin secreting cells inorganic 
phosphate uptake results in further hyperpolarization of the electrical gradient 
(167). Therefore, the significance of this work is the formulation of a novel 
potential mechanism of susceptibility to cisplatin-induced AKI. Thus, NHERF1 
KO mice may have mitochondrial dysfunction due to phosphate wasting that 
sensitizes the kidney to cisplatin toxicity. Seahorse XF24 functional analysis on 
whole kidney tissue would be beneficial for future studies.  
The biotransformation of cisplatin to a nephrotoxin is poorly understood and 
the state of research in the field is encumbered with controversial results. 
Therefore, more research is needed in this area for the development of future 
therapies or early prognostic tests. In Chapter V changes in the renal handling of 
cisplatin were investigated in the NHERF1 KO mouse. First, NHERF1 KO mice 
were confirmed to have increased sensitivity to the initial cisplatin insult. This was 
demonstrated by early histologic signs of damage in the NHERF1 KO kidney 
when compared to WT. Additionally, urine NGAL was significantly increased in 
the 24 hour cisplatin treated NHERF1 KO mouse in comparison to the WT. 
Following that information, lipid peroxidation levels were assessed and found to 
be minimal in vehicle treated WT and NHERF1 KO mice. However, the cisplatin 
treated NHERF1 KO mouse had increased 4-HNE staining in the cortex and JM 
regions when compared to WT. Reduced and oxidized forms of Cys and GSH 
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were compared between WT and NHERF1 KO mice. Although there were some 
differences in vehicle treated NHERF1 KO mice there were no overt signs of 
oxidative stress. GSH levels remained unchanged in both WT and NHERF1 KO 
animals, however, the kidney redox potential in the NHERF1 KO mouse was 
significantly decreased when compared to WT. An increase in redox potential is 
indicative of increased oxidative stress. However, with the increased activity in 
G6PD and ME found in Chapter III, indicators of oxidative stress may be masked. 
Thus, a decrease in redox potential may be a sign of compensatory mechanisms 
to protect from oxidative stress. Finally, since GSH levels were unchanged 
between WT and NHERF1 KO mice it appears the KO mouse has unaltered 
GSH metabolism. In addition to the thiol measurements GGT activity, protein 
level, and localization was also assessed. While the protein level was unchanged 
between all treatment groups the GGT activity response was found to be altered 
with cisplatin treatment in the KO mouse. GGT is important for detoxification of 
xenobiotics and production of GSH, and thus, increased activity may alleviate 
some of the induced oxidative stress from cisplatin. If an increase in GGT activity 
is protective then the NHERF1 KO may not have the ability to increase GGT 
activity quickly and/or robustly with the cisplatin insult, resulting in exacerbated 
injury. Alternatively, if an increase in GGT activity is detrimental, then a 12 hour 
time point may be useful in determining if GGT activity fluctuates over time. 
Therefore, since the KO mouse already has kidney damage at 24 hours there 
could be an increase in activity between 4 and 24 hours resulting in this early 
injury. Another potential explanation for a lack of increase in GGT activity may be 
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due to the histologic changes seen 24 hours after cisplatin treatment, where 
NHERF1 KO mice have patchy areas of BBM sloughing resulting in GGT loss. 
This hypothesis would coincide with data from other studies using 72 hour 
cisplatin treated rats. When the rats exhibited increased damage to the proximal 
tubule the damage corresponded with decreased GGT expression and activity 
(116, 154, 163). Therefore, it is possible that NHERF1 KO mice are beginning to 
lose GGT at 24 hours through BBM sloughing, but have not lost a significant 
amount of GGT protein to be reflected in the western blot data. Finally, CCBL 
protein was also considered in this study. Similar to the GGT protein there were 
no significant changes in CCBL between any of the treatment groups. These 
data provide insight into the effects of NHERF1 loss and renal handling of 
cisplatin. Furthermore, this insight has contributed to upcoming experiments that 
may lead to new hypotheses and therapeutic approaches in the study of 
cisplatin-induced AKI. 
 
D. Strengths and weaknesses of this dissertation 
1. Strengths 
There are several strengths of this dissertation. The first study provides 
insight into the role of NHERF1 loss and metabolic changes in the pentose 
phosphate pathway (Chapter III). The second study (Chapter IV) established that 
NHERF1 KO mice isolated mitochondria do not have structural or functional 
changes that would result in dysfunction. Lastly, Chapter V established that 
NHERF1 KO mice are indeed sensitive to the initial cisplatin insult and have an 
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altered GGT activity response when given cisplatin. Overall this dissertation 
identifies that NHERF1 KO mice respond differently to the cisplatin insult. 
Additionally, it provides novel hypotheses that could lead to potential therapeutic 
approaches or prognostic tests for cisplatin-induced AKI. Currently, no FDA 
approved therapy exists to halt or reverse cisplatin-induced AKI.   
All the work in Chapters III and V was performed in the whole animal. Use of 
the whole animal is particularly important when studying diseases and allows 
better translation to human disease. Chapter IV utilized sensitive approaches in 
establishing mitochondrial changes in the NHERF1 KO mouse. Additionally, 
these studies used multiple time points with an established acute model of 
cisplatin-induced AKI. Furthermore, pharmaceutical grade cisplatin was used 
when treating the animals. While no model fully recapitulates the human disease, 
this model provided an established result of nephrotoxicity in WT C57BL/6J mice. 
Thus, the experimenter can determine changes in response to cisplatin in the 
NHERF1 KO mice. Additionally, the mice used in these experiments were all 
within the same age range (2-4 months old) and were littermates. These steps 
were taken in order to ensure the animals used were young, healthy, and did not 
have genetic drift that may affect the results of these studies. 
The renal circadian clock is known to regulate the dosing-time dependency of 
cisplatin-induced nephrotoxicity in mice (168). All of the mice used in this study 
were treated with cisplatin at approximately 10 a.m. and sacrificed either 24 or 72 
hours later. Unfortunately, the 4 hour time point was conducted earlier at 6 a.m. 
due to restrictions in access to the mice. However, it was deemed to be more 
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important to sacrifice all the animals at the same time point of 10 a.m. This 
decision was made after extensive literature searches, where other studies found 
that when mice were treated with cisplatin later in the day they exhibited less 
kidney injury (169). Thus, this experimental design attempts to mitigate any 
effects of circadian rhythms on cisplatin nephrotoxicity. 
Experimental design is extremely important in mitigating factors that could 
influence results. In addition to using established animal models of cisplatin-
induced AKI and taking into account circadian rhythm, most of these studies 
used five or more animals in each treatment group. This number is due in part to 
the increased sensitivity of the NHERF1 KO mouse to cisplatin and the variability 
in kidney injury seen with cisplatin treatment. As previously mentioned these 
studies also utilized highly sensitive methods for analysis. For instance, LC-MS 
was utilized in order to determine the ATP content of WT and NHERF1 KO 
kidneys. This method is very sensitive and is advantageous when compared to 
commercially available kits used to measure ATP.  
 
2. Weaknesses 
The main purpose of this work was to investigate potential mechanisms of 
susceptibility of the NHERF1 KO mouse to cisplatin nephrotoxicity. In order to 
study the effects NHERF1 loss and its effect before and after cisplatin treatment, 
WT C57BL/6J and C57BL/6J mice with a global deletion of NHERF1 were used. 
Whole mouse deletions can result in non-specific effects due to compensatory 
mechanisms that are selected for early in development. NHERF1 KO mice are 
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viable, fertile, and histologically the kidneys are similar to WT. However, 
NHERF1 KO mice do have alterations in kidney function, phosphate wasting, uric 
acid wasting, and hypercalciuria (46). The potential roles of alterations in 
electrolyte metabolism were not tested in this study. 
Although there are strengths associated with the use of a mouse model, there 
are also limitations. The use of in vivo experiments may recapitulate human 
disease more completely when compared to in vitro experiments. Unfortunately, 
the use of in vivo research also involves less control of variables and introduces 
complexities. Furthermore, relevance to human disease may be questionable 
when mouse models are compared to human studies. At this time the role of 
NHERF1 loss and susceptibility to cisplatin nephrotoxicity has not been studied 
in humans. It is therefore possible that NHERF1 loss is not detrimental or that the 
observed changes in the pentose phosphate pathway and in GGT activity may 
be mouse-specific and have little relevance to humans. While these aspects of in 
vivo models can never be entirely avoided, it can be optimized for the question at 
hand and taken into consideration when interpreting results.  
Other limitations of this study involve the ambiguous and complex process of 
cisplatin biotransformation in the kidney. The controversial role of GGT activity 
has been extensively discussed in this dissertation. However, another limitation 
in studying cisplatin metabolism involves CCBL. Mammals have at least 10 
variations in CCBL, none of which have been conclusively linked with cisplatin 
nephrotoxicity (170). However, glutamine transaminase K (GTK) has a high 
inherent CCBL activity and therefore is the most studied in cisplatin 
 
121 
 
nephrotoxicity. In this dissertation the antibody against CCBL1 or GTK was 
utilized and future activity assays will also be performed using GTK. This added 
complication is another limitation when studying the biotransformation of 
cisplatin. Therefore, any results using GTK may not be relevant in mice let alone 
human subjects.  
 
E. Future Directions 
While the experiments described in this dissertation answered specific gaps 
in our knowledge of NHERF1 loss and susceptibility to cisplatin nephrotoxicity, it 
has also created new questions that will need to be addressed in future studies.  
Seven of these questions are discussed below. 
 
1. Is the increased ME and G6PD activity identified in Chapter III a 
compensatory mechanism to maintain the cellular redox state in 
NHERF1 KO mice? 
In Chapter III ME and G6PD activity was increased in the NHERF1 KO 
mouse and suggested the possibility of increased NADPH production to provide 
protection from oxidative stress. Therefore, measuring NADPH levels in the WT 
and NHERF1 KO kidneys is necessary to answer this question. To carry out this 
investigation LC-MS analysis would be the most sensitive method in measuring 
NADPH levels. Additionally, ATP and NADPH could be measured in cisplatin 
treated animals to further understand the bioenergetics of the NHERF1 KO 
mouse in response to insult. In the previous study cisplatin treated NHERF1 KO 
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mice were found to have increased ATN (35), which may be indicative of 
decreased ATP and/or NADPH levels. In addition, measuring gene and protein 
expression of ME and G6PD could also be investigated to further understand any 
compensatory mechanisms of the NHERF1 KO mouse.  
 
2. Do the NHERF1 KO mitochondria function normally in whole tissue or 
with changes in substrate? 
In Chapter IV NHERF1 KO kidney mitochondria were found to function 
normally in optimal conditions, however this does not answer how the 
mitochondria function in their native environment. Fortunately, Agilent has 
developed Seahorse XF24 islet capture microplates which can be used to 
analyze whole tissue. Furthermore, there have been previous studies using this 
method in multiple tissue types (171-173). Optimization will be needed for the 
kidney, but whole tissue analysis will be useful in determining how NHERF1 KO 
mitochondria function within the kidney. In addition to examining mitochondrial 
function in the kidney, other substrates could be used besides 
succinate/rotenone when assessing isolated mitochondrial function. Agilent also 
has a palmitate-BSA fatty acid oxidation substrate that can be used to assess 
fatty acid oxidation in isolated mitochondria. This consideration is of importance 
as proximal renal tubules use fatty acids as their major source of energy. 
 
3. Does cisplatin damage NHERF1 KO mitochondria to a greater degree 
than WT mitochondria? 
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Cisplatin has been established in inducing ROS and mitochondrial 
dysfunction (139, 140, 142, 143). Furthermore, platinum can be found in 
mitochondria 24 hours after cisplatin treatment. This information combined with 
studies from Chapter IV gives rise to multiple future experiments. WT and 
NHERF1 KO mice could be treated with cisplatin for 24 and 72 hours and 
mitochondria can be isolated from these kidneys for Seahorse XF24 functional 
analysis and measurement of platinum by inductively coupled plasma-mass 
spectrometry (ICP-MS). Additionally, ROS could be measured in isolated 
mitochondria using mitoSOX for mitochondrial O2 detection. These studies could 
help in understanding if cisplatin is taken up to a greater degree in NHERF1 KO 
mitochondria and if cisplatin damages these mitochondria to a greater degree 
resulting in enhanced injury.  
 
4.  Does NHERF1 loss result in altered renal handling of cisplatin 
besides GGT activity? 
In addition to GGT activity CCBL activity can also be measured between 
vehicle and cisplatin treated WT and NHERF1 KO mice. There are multiple 
methods to assess CCBL activity, however GTK activity assay is simple and has 
been well studied (174). Additionally, IHC can be utilized to assess CCBL 
localization in vehicle and cisplatin treated WT and NHERF1 KO kidneys. ICP-
MS can also be used to measure platinum levels between cisplatin treated WT 
and NHERF1 KO kidneys. An increase in platinum in the NHERF1 KO kidney 
could indicate altered uptake or extrusion of cisplatin. Higher concentrations of 
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cisplatin have been associated with increased necrotic cell death which was seen 
in the 72 hour cisplatin treated NHERF1 KO mouse (35). Furthermore, WT and 
NHERF1 KO mice could be treated with known inhibitors for OCT2, MATE1, and 
GGT in order to determine if the KO mouse responds the same and exhibits 
either amelioration or enhancement of toxicity. These outcomes could help to 
identify key players in the susceptibility of the NHERF1 KO mouse to cisplatin 
nephrotoxicity. Lastly, OK and NHERF1 deficient OK proximal tubule cells could 
be used to overexpress GGT to evaluate the effect of increased GGT expression 
on activity after treatment with cisplatin. This information would again, help to 
elucidate if increased GGT activity is detrimental or protective with NHERF1 loss 
and cisplatin treatment. 
 
5. How do NHERF1 KO mice respond to a chronic model of cisplatin 
nephrotoxicity? 
Utilization of a chronic repeated dosing model of cisplatin nephrotoxicity could 
help in determining if NHERF1 KO mice are only sensitive to an acute high dose 
of cisplatin or if they are equally sensitive to lower repeated doses over time. In 
WT mice the kidney damage associated with the chronic model is less severe 
and results in longer survival (175). Studying NHERF1 loss and cisplatin 
nephrotoxicity in a chronic model could provide information in understanding 
conditions when NHERF1 loss is detrimental with cisplatin administration. 
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6. Do heterozygous NHERF1 KO mice have some protection to cisplatin 
nephrotoxicity? 
All of the studies mentioned in this dissertation have been conducted with 
complete loss of the NHERF1 protein. To broaden our knowledge of 
susceptibility to cisplatin nephrotoxicity with NHERF1 loss, heterozygous mice 
could also be tested using the acute cisplatin model. This could help answer the 
following questions: [1] is complete loss of NHERF1 expression needed for 
susceptibility to cisplatin nephrotoxicity and [2] is there a percent loss of NHERF1 
that predisposes these animals to cisplatin nephrotoxicity? 
 
7. Does NHERF1 loss predispose mouse kidneys to other nephrotoxins 
or forms of AKI? 
These studies have only evaluated the nephrotoxic effects of cisplatin in 
NHERF1 KO mice. It would be interesting to establish if these mice are only 
sensitive to cisplatin or if other nephrotoxins also result in enhanced injury. For 
example, cyclosporine, vancomycin, acyclovir, lead, mercury, and cadmium 
could be tested. In addition, models of ischemic reperfusion could also be 
evaluated.  
 
F. Summary and conclusions 
The overall goal of the work described in this dissertation was to discover new 
potential mechanisms and hypotheses for susceptibility to cisplatin-induced AKI 
with NHERF1 loss. Chapter III evaluated metabolic alterations in the NHERF1 
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KO mouse that may play a role in the susceptibility to cisplatin insult. This study 
provided the foundation for new hypotheses and future experiments concerning 
changes in NADPH production in the NHERF1 KO mouse and masked signs of 
oxidative stress that may predispose these animals to injury. Chapter IV aimed to 
evaluate if NHERF1 KO mice had an underlying mitochondrial dysfunction due 
to: [1] decreases in mitochondrial oxidative capacity and/or alterations in the 
structure of NHERF1 KO kidneys [2] decreases in number of mitochondria in 
NHERF1 KO kidney. This study did not find any evidence of mitochondrial 
dysfunction in the NHERF1 KO mouse. Finally, Chapter V assessed if NHERF1 
loss resulted in altered renal handling of cisplatin and found an altered GGT 
activity response when NHERF1 KO mice were given cisplatin. Taken together, 
these studies provide new insight into the mechanism of susceptibility of 
NHERF1 loss in cisplatin-induced AKI.  
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ABBREVIATIONS 
 
ACEI Angiotensin converting enzyme inhibitors 
AGN Acute glomerulonephritis 
AIN Acute interstitial nephritis 
AKI Acute kidney injury 
ANOVA Analysis of variance 
AP Aminopeptidase 
ARB Angiotensin receptor blockers 
ATN Acute tubular necrosis 
ATPase Adenosine triphosphatase 
BBM Brush border membrane 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
BUN Blood urea nitrogen 
CCBL Cysteine-S-conjugate beta lyase 
CCBL1 Alternative name for glutamate transaminase k 
CKD Chronic kidney disease 
CRAC Cholesterol binding domain 
Ctr1 Copper transporter 1 
CySSG Cysteine-glutathione disulfide 
Cys Cysteine 
CySS Cystine 
CXCR2 C-X-C motif chemokine receptor 2 
E. coli Escherichia coli 
EGFR Epidermal growth factor receptor 
EGTA Ethylene glycol tetraacetic acid 
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ELISA Enzyme-linked immunosorbent assay 
EM Electron microscopy 
EMT Epithelial-mesenchymal-transition 
ERM Ezrin-radixin-moesin 
ETC Electron transport chain 
FBPase Fructose-1,6-bisphosphatase 
FDA Food and drug administration 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GFR Glomerular filtration rate 
GGT γ glutamyl transpeptidase or transferase 
GI Gastrointestinal 
GPCRs G-protein-coupled-receptors 
GSH Glutathione 
GSSG Glutathione disulfide 
GTK Glutamate transaminase k 
G6Pase Glucose-6-phosphatase 
G6PD Glucose-6-phosphate dehydrogenase 
HEPES 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid 
H&E Hematoxylin and eosin 
HPLC High-performance-liquid-chromatography 
IACUC Institutional animal care and use committee 
ICAM-1 Intracellular adhesion molecule 1 
ICU Intensive care unit 
IHC Immunohistochemistry 
IL8 Interleukin 8 
IP Intraperitoneal 
JM Juxtamedullary 
KO Knock out  
LC-MS Liquid chromatography-mass spectrometry 
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LDH Lactate dehydrogenase 
MATE1 Multidrug and toxin extrusion 1 
MDA Malondialdehyde 
MDCK Madrin-darby-canine-kidney 
MDH Malate dehydrogenase 
MOPS 3-(N-morpholino)propanesulonic acid 
mOsm/kg Milliosmoles per kilogram 
ME Malic enzyme 
NF-B 
Nuclear factor kappa-light chain enhancer of activated B 
cells 
NGAL Neutrophil gelatinase-associated lipocalin 
NHERF1 Na/H exchange regulatory factor 1 
NHE3 Sodium hydrogen antiporter 3 
Nox1 NADPD oxidase 
Npt2a Sodium phosphate co-transporter type-2 
NSAID Nonsteroidal anti-inflammatory drug 
OCR Oxygen consumption rate 
OCT2 Organic cation transporter 2 
OK Opossum kidney 
PAS Periodic acid-schiff 
PBS Phosphate buffered saline 
PDZ 
Post-synaptic density protein 95/drosophila discs 
large/zonulaocculens-1 
Pt Platinum 
PTH Parathyroid hormone 
RCR Respiratory control ratio 
ROCK Rho-associated coiled-coil containing protein kinase 
ROS Reactive oxygen species 
SEM  Standard error means 
SNP Single-nucleotide polymorphism 
Stat3 Single transducer and activator of transcription 3 
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TBARS Thiobarbituric acid reactive substances 
TCA Trichloroacetic acid 
TGF-β1 Transforming growth factor beta 1 
TTBS Tris-buffered saline with 0.5% Tween 20 
WT Wild type 
VEGF Vascular endothelial growth factor 
4-HNE 4-hydroxylnonenal 
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NHERF1 in cisplatin-induced acute kidney injury. Research!Louisville Abs. 
#GRM-3, October 11-13, 2016, Louisville, KY. 
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2. Bushau-Sprinkle A., Conklin C., Barati M., Brier M., Coventry S., Dupre 
T., Siskind L., Rane M., and Lederer E. (2017) NHERF1 deficiency 
increases susceptibility to cisplatin-induced acute kidney injury. American 
Society of Nephrology Kidney Week Abs. #TH-PO306, November 1-5, 
2017, New Orleans, LA. 
3. Bushau-Sprinkle A., Sherwood A., Conklin C., Barati M., Dupre T., 
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Biology Annual Meeting, Orlando, FL, 
5. Poster, 10/18, NHERF1 loss results in metabolic stress and increased 
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